<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        362-212-17
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2017
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        VENEX XR 37.5 MG CAPSULE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        VENLAFAXINE HYDROCHLORIDE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        37.5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Modified-release capsule
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        14
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        do not store above 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        27.05
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="PHARMATHEN INTERNATIONAL" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            PHARMATHEN INTERNATIONAL
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 488]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SPIMACO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            SPIMACO ADDWAEIH
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        N06AX16
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Venex XR is an antidepressant that belongs to a group of medicines called serotonin and<br />&nbsp;norepinephrine reuptake inhibitors (SNRIs). This group of medicines is used to treat depression and other conditions such as anxiety disorders. It is thought that people who are depressed and/or anxious have lower levels of serotonin and noradrenaline in the brain. It is not fully understood how antidepressants work, but they may help by increasing the levels of serotonin and noradrenaline in the brain.<br />Venex XR is a treatment for adults with depression. Venex XR is also a treatment for adults with social anxiety disorder (fear or avoidance of social situations). Treating depression or social anxiety disorder properly is important to help you get better. If it is not treated, your condition may not go away and may become more serious and more difficult to treat.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not take Venex XR &bull; If you are allergic to Venex XR or any of the other ingredients of Venex XR. &bull; If you are also taking or have taken any time within the last 14 days any medicines known as irreversible monoamine oxidase inhibitors (MAOIs), used to treat depression or Parkinson&rsquo;s disease. Taking an irreversible MAOI together with other medicines, including Venex XR, can cause serious or even lifethreatening side effects. Also, you must wait at least 7 days after you stop taking Venex XR before you take any MAOI (see also the sections &ldquo;Serotonin syndrome&rdquo; and &ldquo;Taking other medicines&rdquo;). Take special care with Venex XR &bull; If you use other medicines that taken concomitantly with Venex XR could increase the risk of developing serotonin syndrome (see the section &ldquo;Taking other medicines&rdquo;). &bull; If you have eye problems, such as certain kinds of glaucoma (increased pressure in the eye). &bull; If you have a history of high blood pressure. &bull; If you have a history of heart problems. &bull; If you have a history of fits (seizures). &bull; If you have a history of low sodium levels in your blood (hyponatraemia). &bull; If your cholesterol levels get higher. &bull; If you have been told you have an abnormal heart rhythm. &bull; If you have a tendency to develop bruises or a tendency to bleed easily (history of bleeding disorders), or if you are taking other medicines that may increase the risk of bleeding e.g., warfarin (used to prevent blood clots). &bull; If you have a history of, or if someone in your family has had, mania or bipolar disorder (feeling over-excited or euphoric). &bull; If you have a history of aggressive behavior. Venex XR may cause a sensation of restlessness or an inability to sit or stand still. You should tell your doctor if this happens to you.If any of these conditions apply to you, please talk with your doctor before taking Venex XR. Thoughts of suicide and worsening of your depression or anxiety disorder<br />If you are depressed and/or have anxiety disorders, you can sometimes have thoughts of harming or killing yourself. These may be increased when you first start taking antidepressants, since these medicines all take time to work, usually about two weeks, but sometimes longer.<br />You may be more likely to think like this: &bull; If you have previously had thoughts about killing yourself or harming yourself. &bull; If you are a young adult. Information from clinical trials has shown an increased risk of suicidal behavior in young adults (less than 25 years old) with psychiatric conditions who were treated with an antidepressant.<br />If you have thoughts of harming or killing yourself at any time, contact your doctor or go to a hospital straight away.<br />You may find it helpful to tell a relative or close friend that you are depressed or have an anxiety disorder, and ask them to read this leaflet. You might ask them to tell you if they think your depression or anxiety is getting worse, or if they are worried about changes in your behavior.<br />Diabetes: Your blood glucose levels may be altered due to Venex XR. Therefore, the dosage of your diabetes medicines may need to be adjusted. Dry mouth Dry mouth is reported in 10% of patients treated with Venex XR. This may increase the risk of caries. Therefore, you should take special care in your dental hygiene. Use in children and adolescents under 18 years of age<br />Venex XR should normally not be used for children and adolescents under 18 years. Also, you should know that patients under 18 have an increased risk of side effects, such as suicide attempt, suicidal thoughts and hostility (predominantly aggression, oppositional behaviour and anger) when they take this class of medicines. Despite this, your doctor may prescribe Venex XR for patients under 18 because he/she decides that this is in their best interests. If your doctor has prescribed Venex XR for a patient under 18, and you want to discuss this, please go back to your doctor. You should inform your doctor if any of the symptoms listed above develop or worsen when patients under 18 are taking Venex XR. Also, the long-term safety effects concerning growth, maturation and cognitive and behavioural development of Venex XR in this age group has not yet been demonstrated.<br />Taking other medicines&nbsp;Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription. Your doctor should decide whether you can take Venex XR with other medicines. Do not start or stop taking any medicines, including those bought without a prescription, natural and herbal remedies, before checking with your doctor or pharmacist. &bull; Monoamine oxidase inhibitors which are used to treat depression or Parkinson&rsquo;s disease must not be taken with Venex XR. Tell your doctor if you have taken these medicines within the last 14days. (MAOIs: see the section &ldquo;Before you take Venex XR&rdquo;). &bull; Serotonin syndrome: A potentially life-threatening condition or Neuroleptic Malignant Syndrome (NMS)like reactions (see the section &ldquo;Possible Side Effects&rdquo;), may occur with venlafaxine treatment, particularly when taken with other medicines. Examples of these medicines include:  Triptans (used for migraine)  Other medicines to treat depression, for instance SNRIs, SSRIs, tricyclics, or medicines containing lithium  Medicines containing linezolid, an antibiotic (used to treat infections)  Medicines containing moclobemide, a MAOI (used to treat depression)  Medicines containing sibutramine (used for weight loss)  Medicines containing tramadol, fentanyl, tapentadol, pethidine, or pentazocine (used to treat severe pain)  Medicines containing dextromethorphan (used to treat coughing)  Medicines containing methadone (used to treat opioid drug addiction or severe pain)  Medicines containing methylene blue (used to treat high levels of methaemoglobin in the blood)  Products containing St. John&rsquo;s Wort (also called Hypericum perforatum, a natural or herbal remedy used to treat mild depression)  Products containing tryptophan (used for problems such as sleep and depression)  Antipsychotics (used to treat a disease with symptoms such as hearing, seeing or sensing things which are not there, mistaken beliefs, unusual suspiciousness, unclear reasoning and becoming withdrawn) Signs and symptoms of serotonin syndrome may include a combination of the following: Restlessness, hallucinations, loss of coordination, fast heart beat, increased body temperature, fast changes in blood pressure, overactive reflexes, diarrhoea, coma, nausea, vomiting. In its most severe form, serotonin syndrome can resemble Neuroleptic Malignant Syndrome (NMS). Signs and symptoms of NMS may include a combination of fever, fast heart beat, sweating, severe muscle stiffness, confusion, increased muscle enzymes (determined by a blood test). Tell your doctor immediately, or go to the casualty department at your nearest hospital if you think serotonin syndrome is happening to you.<br />&nbsp;<br />&nbsp;You must tell your doctor if you are taking medicines that can affect your heart rhythm. Examples of these medicines include: &bull; Antiarrhythmics such as quinidine, amiodarone, sotalol or dofetilide (used to treat abnormal heart rhythm) &bull; Antipsychotics such as thioridazine (See also Serotonin syndrome above) &bull; Antibiotics such as erythromycin or moxifloxacin (used to treat bacterial infections) &bull; Antihistamines (used to treat allergy) The following medicines may also interact with Venex XR and should be used with caution. It is especially important to mention to your doctor or pharmacist if you are taking medicines containing: &bull; Ketoconazole (an antifungal medicine) &bull; Haloperidol or risperidone (to treat psychiatric conditions) &bull; Metoprolol (a beta blocker to treat high blood pressure and heart problems) Taking Venex XR with food and drink Venex XR should be taken with food (see section 3 &ldquo;HOW TO TAKE Venex XR&rdquo;). You should avoid alcohol while you are taking Venex XR. Pregnancy and breast-feeding<br />Tell your doctor if you become pregnant, or you are trying to become pregnant. You should use Venex XR only after discussing the potential benefits and the potential risks to your unborn child with your doctor. Make sure your midwife and/or doctor knows you are on Venex XR. When taken during pregnancy, similar drugs (SSRIs) may increase the risk of serious condition in babies, called persistent pulmonary hypertension of the newborn (PPHN), making the baby breathe faster and appear bluish. These symptoms usually begin during the first 24 hours after the baby is born. If this happens to your baby you should contact your midwife and/or doctor immediately.<br />Venex XR passes into breast milk. There is a risk of an effect on the baby. Therefore, you should discuss the matter with your doctor, and he/she will decide whether you should stop breast-feeding or stop the therapy with Venex XR. If you are taking this medicine during pregnancy, other symptoms your baby might have when it is born is not feeding properly, in addition to having trouble breathing. If your baby has these symptoms when it is born and you are concerned, contact your doctor and/or midwife who will be able to advise you. Driving and using machines Do not drive or use any tools or machines until you know how Venex XR affects you.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take Venex XR exactly as your doctor has told you. You should check with your doctor or pharmacist if you are not sure.<br />The usual recommended starting dose for treatment of depression and social anxiety<br />&nbsp;disorder is 75 mg per day. The dose can be raised by your doctor gradually, and if needed, even up to a maximum dose of 375 mg daily for depression. If you are being treated for panic disorder, your doctor will start with a lower dose (37.5 mg) and then increase the dose gradually. The maximum dose for social anxiety disorder is 225 mg/day.<br />Take Venex XR at approximately the same time each day, either in the morning or in the evening. Capsules must be swallowed whole with fluid and not opened, crushed, chewed or dissolved. Venex XR should be taken with food.<br />If you have liver or kidney problems, talk to your doctor, since your dose of Venex XR may need to be different. Do not stop taking Venex XR without talking to your doctor (see the section &ldquo;If you stop taking Venex XR&rdquo;). If you take more Venex XR than you should<br />Call your doctor or pharmacist immediately if you take more than the amount of Venex XR prescribed by your doctor.<br />The symptoms of a possible overdose may include a rapid heartbeat, changes in level of alertness (ranging from sleepiness to coma), blurred vision, seizures or fits, and vomiting. If you forget to take Venex XR<br />If you miss a dose, take it as soon as you remember. However, if it is time for your next dose, skip the missed dose and take only a single dose as usual. Do not take more than the daily amount of Venex XR that has been prescribed for you in one day. If you stop taking Venex XR<br />Do not stop taking your treatment or reduce the dose without the advice of your doctor even if you feel better. If your doctor thinks that you no longer need Venex XR , he/she may ask you to reduce your dose slowly before stopping treatment altogether. Side effects are known to occur when people stop using Venex XR, especially when Venex XR is stopped suddenly or the dose is reduced too quickly. Some patients may experience symptoms such as tiredness, dizziness, light-headedness, headache, sleeplessness, nightmares, dry mouth, loss of appetite, diarrhea, nervousness, agitation, confusion, ringing in the ears, tingling or rarely electric shock sensations, weakness, sweating, seizures, or flu-like symptoms.<br />Your doctor will advise you on how you should gradually discontinue Venex XR treatment. If you experience any of these or other symptoms that are troublesome, ask your doctor for further advice.<br />If you have any further questions on the use of this product, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, Venex XR can cause side effects, although not everybody gets them. If any of the following happen, do not take more Venex XR. Tell your doctor immediately, or go to the casualty department at your nearest hospital: &bull; Chest tightness, wheezing, trouble swallowing or breathing &bull; Swelling of the face, throat, hands, or feet &bull; Feeling nervous or anxious, dizziness, throbbing sensations, sudden reddening of the skin and/or a warm feeling &bull; Severe rash, itching, or hives (elevated patches of red or pale skin that often itch) &bull; Signs and symptoms of serotonin syndrome which may include restlessness, hallucinations, loss of coordination, fast heart beat, increased body temperature, fast changes in blood pressure, overactive reflexes, diarrhoea, coma, nausea, vomiting. In its most severe form, serotonin syndrome can resemble Neuroleptic Malignant Syndrome (NMS). Signs and symptoms of NMS may include a combination of fever, fast heart beat, sweating, severe muscle stiffness, confusion, increased muscle enzymes (determined by a blood test). Other side effects that you should tell your doctor about include: &bull; Coughing, wheezing, shortness of breath and a high temperature &bull; Black (tarry) stools or blood in stools &bull; Yellow skin or eyes, itchiness or dark urine, which may be symptoms of inflammation of the liver (hepatitis) &bull; Heart problems, such as fast or irregular heart rate, increased blood pressure &bull; Eye problems, such as blurred vision, dilated pupils &bull; Nerve problems, such as dizziness, pins and needles, movement disorder, seizures or fits &bull; Psychiatric problems, such as hyperactivity and euphoria (feeling unusually overexcited). &bull; Withdrawal effects (see the section &ldquo;HOW TO TAKE VENEX XR, if you stop taking Venex XR&rdquo;). &bull; Prolonged bleeding - if you cut or injure yourself, it may take slightly longer than usual for bleeding to stop.<br />Complete side effect listing<br />Very common (affects more than 1 in 10 users) &bull; Dizziness; headache &bull; Nausea; dry mouth &bull; Sweating (including night sweats) Common (affects 1 to 10 users in 100) &bull; Appetite decreased &bull; Confusion; feeling separated (or detached) from yourself; lack of orgasm; decreased libido; nervousness; insomnia; abnormal dreams &bull; Drowsiness; tremor; pins and needles; increased muscle tonus &bull; Visual disturbance including blurred vision; dilated pupils; inability of the eye to automatically change focus from distant to near objects &bull; Ringing in the ears (tinnitus) &bull; Palpitations&nbsp;&bull; Increase in blood pressure; flushing; &bull; Yawning &bull; Vomiting; constipation; diarrhoea &bull; Increased frequency in urination; difficulties passing urine &bull; Menstrual irregularities such as increased bleeding or increased irregular bleeding; abnormal ejaculation/orgasm (males); erectile dysfunction (impotence) &bull; Weakness (asthenia); fatigue; chills &bull; Increased cholesterol Uncommon (affects 1 to 10 users in 1,000) &bull; Hallucinations; feeling separated (or detached) from reality; agitation; abnormal orgasm (females); lack of feeling or emotion; feeling over-excited; grinding of the teeth &bull; A sensation of restlessness or an inability to sit or stand still; fainting; involuntary movements of the muscles; impaired coordination and balance; altered taste sensation &bull; Fast heartbeat; feeling dizzy (particularly when standing up too quickly) &bull; Shortness of breath &bull; Vomiting blood, black tarry stools (faeces) or blood in stools; which can be a sign of internal bleeding &bull; General swelling of the skin especially the face, mouth, tongue, throat area or hands and feet and/or a raised itchy rash (hives) may be present; sensitivity to sunlight; bruising; rash; abnormal hair loss &bull; Inability to pass urine; &bull; Weight gain; weight loss<br />Rare (affects 1 to 10 users in 10,000) &bull; Seizures or fits &bull; Inability to control urination &bull; Over activity, racing thoughts and decreased need for sleep (mania) Frequency not known &bull; Reduced number of platelets in your blood, leading to an increased risk of bruising or bleeding; blood disorders which may lead to an increased risk of infection &bull; Swollen face or tongue, shortness of breath or difficulty breathing, often with skin rashes (this may be a serious allergic reaction) &bull; Excessive water intake (known as SIADH) &bull; Decrease in blood sodium levels &bull; Suicidal ideation and suicidal behaviours; cases of suicidal ideation and suicidal behaviours have been reported during venlafaxine therapy or early after treatment discontinuation (see section 2, Before you take Venex XR) &bull; Disorientation and confusion often accompanied by hallucination (delirium); aggression &bull; A high temperature with rigid muscles, confusion or agitation, and sweating, or if you experience jerky muscle movements which you can&#39;t control, these may be symptoms of serious conditions known as neuroleptic malignant syndrome; euphoric feelings, drowsiness, sustained rapid eye movement, clumsiness, restlessness, feeling of being drunk, sweating or rigid muscles, which are&nbsp;symptoms of serotonin syndrome; stiffness, spasms and involuntary movements of the muscles &bull; Severe eye pain and decreased or blurred vision &bull; Vertigo &bull; Decrease in blood pressure; abnormal, rapid or irregular heart beat, which could lead to fainting; unexpected bleeding, e.g. bleeding gums, blood in the urine or in vomit, or the appearance of unexpected bruises or broken blood vessels (broken veins) &bull; Coughing, wheezing, shortness of breath and a high temperature, which are symptoms of inflammation of the lungs associated with an increase in white blood cells (pulmonary eosinophilia) &bull; Severe abdominal or back pains (which could indicate a serious problem in the gut, liver or pancreas) &bull; Itchiness, yellow skin or eyes, dark urine, or flu-like symptoms, which are symptoms of inflammation of the liver (hepatitis); slight changes in blood levels of liver enzymes &bull; Skin rash, which may lead to severe blistering and peeling of the skin; itching; mild rash &bull; Unexplained muscle pain, tenderness or weakness (rhabdomyolysis) &bull; Abnormal breast milk production<br />Venex XR sometimes causes unwanted effects that you may not be aware of, such as increases in blood pressure or abnormal heart beat; slight changes in blood levels or liver enzymes, sodium or cholesterol. More rarely, Venex XR may reduce the function of platelets in your blood, leading to an increased risk of bruising or bleeding. Therefore, your doctor may wish to do blood tests occasionally, particularly if you have been taking Venex XR for a long time.<br />If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.<br /><br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep out of the reach and sight of children.<br />Do not use Venex XR after the expiry date, which is stated on the packaging. The expiry date refers to the last day of that month. Store below 30&ordm;C.<br />Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is Venlafaxine.<br />Each prolonged-release capsule, hard contains 37.5 mg, 75 mg and 150 mg of Venex XR as venlafaxine hydrochloride&nbsp;</p><p>The other ingredients are: 37.5 mg prolonged-release capsules, hard: Capsule content: Hydromellose (Methocel K 100M), Eudragit RS 100 powder, Sodium lauryl sulphate, Magnesium stearate, and ethanol Coating: Eudragit E 12.5, and Isopropyl alcohol</p><p>&nbsp;Capsule shell: Titanium Dioxide E 171, Gelatin<br />75 mg prolonged-release capsules, hard: Capsule content: Hydromellose (Methocel K 100M), Eudragit RS 100 powder, Sodium lauryl sulphate, Magnesium stearate Coating: Eudragit E 100<br />Capsule shell: Titanium Dioxide E 171, Iron Oxide (Red) E172, Gelatin<br />150 mg prolonged-release capsules, hard:<br />Capsule content: Hydromellose (Methocel K 100M), Eudragit RS 100 powder, Sodium lauryl sulphate, Magnesium stearate Coating: Eudragit E 100<br />Capsule shell: Titanium Dioxide E 171, Erythrosine E 127, Indigo Carmine E132, Gelatin</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                37.5 mg prolonged-release capsules, hard:a white opaque-white opaque size 0 hard gelatin capsules containing 37.5 mg Venlafaxine.
75 mg prolonged-release capsules, hard: flesh opaque size 0 hard gelatin capsules containing 75 mgVenlafaxine.
150 mg prolonged-release capsules, hard: scarlet opaque size 00 hard gelatin capsules containing 150 mg Venlafaxine.
Pack sizes: 2×blister of 7 caps

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>SPIMACO AlQassim pharmaceutical plant Saudi Pharmaceutical Industries &amp; Medical Appliance Corporation. Saudi Arabia<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last approved in December 2015.
 
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>ﻓﯿﻨﯿﻜﺲ م.م. ھﻮ دواء ﻣﻀﺎد ﻟﻼﻛﺘﺌﺎب، وھﻮ ﯾﻨﺘﻤﻰ إﻟﻰ ﻣﺠﻤﻮﻋﺔ ﻣﻦ اﻷدوﯾﺔ ﺗﻌﺮف ﺑﺎﺳﻢ ﻣﺜﺒﻄﺎت اﺳﺘﺮداد اﻟﺴﯿﺮوﺗﻮﻧﯿﻦ</p><p>واﻟﻨﻮرإﺑﯿﻨﯿﻔﺮﯾﻦ .(SNRIs) ﺗﺴﺘﺨﺪم ھﺬه اﻟﻤﺠﻤﻮﻋﺔ ﻣﻦ اﻷدوﯾﺔ ﻟﻌﻼج اﻻﻛﺘﺌﺎب وﺑﻌﺾ اﻟﺤﺎﻻت اﻷﺧﺮى ﻣﺜﻞ اﺿﻄﺮاﺑﺎت</p><p>اﻟﻘﻠﻖ. ﺣﯿﺚ أﻧﮫ ﯾﻌﺘﻘﺪ أن اﻷﺷﺨﺎص اﻟﻤﺼﺎﺑﯿﻦ ﺑﺎﻻﻛﺘﺌﺎب و/ أو اﻟﻘﻠﻖ ﻟﺪﯾﮭﻢ ﻣﺴﺘﻮﯾﺎت ﻣﻨﺨﻔﺾ ﻣﻦ اﻟﺴﯿﺮوﺗﻮﻧﯿﻦ واﻟﻨﻮرأدرﯾﻨﺎﻟﯿﻦ ﺑﺎﻟﻤﺦ. ﻛﯿﻔﯿﺔ ﻋﻤﻞ ﻣﻀﺎدات اﻻﻛﺘﺌﺎب ﻟﯿﺴﺖ ﻣﻔﮭﻮﻣﺔ ﺑﺎﻟﺸﻜﻞ اﻟﻜﺎﻣﻞ، ﻟﻜﻨﮭﺎ ﻗﺪ ﺗﺴﺎﻋﺪ ﻋﻦ طﺮﯾﻖ زﯾﺎدة ﻣﺴﺘﻮﯾﺎت اﻟﺴﯿﺮوﺗﻮﻧﯿﻦ</p><p>واﻟﻨﻮرأدرﯾﻨﺎﻟﯿﻦ ﺑﺎﻟﻤﺦ.</p><p>&nbsp;</p><p>ﯾﺴﺘﺨﺪم أﯾﻀﺎ ﻟﻌﻼج اﻷﺷﺨﺎص اﻟﺒﺎﻟﻐﯿﻦ</p><p>&nbsp;</p><p>ﻓﯿﻨﯿﻜﺲ م.م.</p><p>&nbsp;</p><p>ﯾﺴﺘﺨﺪم ﻟﻌﻼج اﻷﺷﺨﺎص اﻟﺒﺎﻟﻐﯿﻦ اﻟﻤﺼﺎﺑﯿﻦ ﺑﺎﻻﻛﺘﺌﺎب.</p><p>&nbsp;</p><p>ﻓﯿﻨﯿﻜﺲ م.م.</p><p>&nbsp;</p><p>اﻟﻤﺼﺎﺑﯿﻦ ﺑﺎﺿﻄﺮاﺑﺎت اﻟﻘﻠﻖ اﻻﺟﺘﻤﺎﻋﻰ )اﻟﺨﻮف ﻣﻦ أو ﺗﺠﻨﺐ اﻟﻤﻮاﻗﻒ اﻻﺟﺘﻤﺎﻋﯿﺔ.( ﻣﻦ اﻟﻤﮭﻢ ﻋﻼج اﻻﻛﺘﺌﺎب واﺿﻄﺮاﺑﺎت</p><p>اﻟﻘﻠﻖ اﻻﺟﺘﻤﺎﻋﻰ ﺑﺸﻜﻞ ﺳﻠﯿﻢ ﻟﺘﺴﺎﻋﺪك ﻋﻠﻰ اﻟﺸﻌﻮر ﺑﺘﺤﺴﻦ. ﻓﻰ ﺣﺎﻟﺔ ﻋﺪم اﻟﻌﻼج ﻗﺪ ﺗﺴﻮء ﺣﺎﻟﺘﻚ أﻛﺜﺮ ﻣﻦ ذى ﻗﺒﻞ وﺗﺼﺒﺢ&nbsp;أﻛﺜﺮ ﺻﻌﻮﺑﺔ وﻗﺪ ﻻﺗﺸﻔﻰ أﺑﺪا.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>اﻣﺘﻨﻊ ﻋﻦ ﺗﻨﺎول أﻗﺮاص ﻓﯿﻨﯿﻜﺲ م.م. وأﺧﺒﺮ طﺒﯿﺒﻚ ﻓﻰ اﻟﺤﺎﻻت اﻵﺗﯿﺔ:</p><p>&bull; إذا ﻛﻨﺖ ﺗﻌﺎﻧﻲ ﻣﻦ ﻓﺮط اﻟﺘﺤﺴﺲ ﻟﻔﯿﻨﯿﻜﺲ م.م.، أو أى ﻣﻦ اﻟﻤﻜﻮﻧﺎت اﻷﺧﺮى ﻟﻔﯿﻨﯿﻜﺲ م.م..</p><p>&bull; إذا ﻛﻨﺖ ﺗﺘﻨﺎول ﺣﺎﻟﯿﺎ أو ﻓﻰ ﺧﻼل ﻓﺘﺮة ال٤١ ﯾﻮم اﻟﺴﺎﺑﻘﺔ أﯾﺎ ﻣﻦ اﻷدوﯾﺔ اﻟﺘﻰ ﺗﻌﺮف ﺑﺎﺳﻢ اﻟﻤﺜﺒﻄﺎت اﻟﻼﻋﻜﺴﯿﺔ ﻹﻧﺰﯾﻢ ﻣﻮﻧﻮ</p><p>أﻣﯿﻦ أوﻛﺴﯿﺪﯾﺰ (MAOIs)، واﻟﺘﻰ ﺗﺴﺘﺨﺪم ﻟﻌﻼج اﻻﻛﺘﺌﺎب أوﻣﺮض ﺑﺎرﻛﻨﺴﻮن. ﺗﻨﺎول اﻟﻤﺜﺒﻄﺎت اﻟﻼﻋﻜﺴﯿﺔ &nbsp;ﻹﻧﺰﯾﻢ ﻣﻮﻧﻮ</p><p>أﻣﯿﻦ أﻛﺴﯿﺪﯾﺰ (MAOIs) ﻣﻊ ﺑﻌﺾ اﻷدوﯾﺔ اﻷﺧﺮى، وﺗﺸﻤﻞ ﻓﯿﻨﯿﻜﺲ م.م. ﻗﺪ ﯾﺴﺒﺐ أﻋﺮاض ﺟﺎﻧﺒﯿﺔ ﺧﻄﯿﺮة وﻗﺪ ﯾﮭﺪد اﻟﺤﯿﺎة. أﯾﻀﺎ ﯾﺠﺐ ﻋﻠﯿﻚ أن ﺗﻨﺘﻈﺮ ﻟﻤﺪة ﻻ ﺗﻘﻞ ﻋﻦ ٧ أﯾﺎم ﺑﻌﺪ اﻟﺘﻮﻗﻒ ﻋﻦ ﺗﻨﺎول ﻓﯿﻨﯿﻜﺲ م.م. ﻗﺒﻞ اﻟﺒﺪء ﻓﻰ ﺗﻨﺎول أﯾﺎ ﻣﻦ ﻣﺜﺒﻄﺎت إﻧﺰﯾﻢ</p><p>ﻣﻮﻧﻮ أﻣﯿﻦ أوﻛﺴﯿﺪﯾﺰ )اﻧﻈﺮ أﯾﻀﺎ إﻟﻰ اﻟﻔﻘﺮﺗﯿﻦ &raquo;ﻣﺘﻼزﻣﺔ اﻟﺴﯿﺮوﺗﻮﻧﯿﻦ&laquo; و &raquo;ﺗﻨﺎول ﺑﻌﺾ اﻷدوﯾﺔ اﻷﺧﺮى.(&laquo;</p><p>ﯾﻨﺒﻐﻰ ﺗﻮﺧﻰ اﻟﺤﺬر ﻋﻨﺪ ﺗﻨﺎول أﻗﺮاص ﻓﯿﻨﯿﻜﺲ م.م. ﻓﻰ اﻟﺤﻼت اﻵﺗﯿﺔ:</p><p>&bull; &nbsp;إذا ﻛﻨﺖ ﺗﺘﻨﺎول ﺑﻌﺾ اﻷدوﯾﺔ اﻷﺧﺮى واﻟﺘﻰ ﻋﻨﺪﻣﺎ ﺗﺆﺧﺬ ﺑﺼﻮرة ﻣﺘﺰاﻣﻨﺔ ﻣﻊ ﻓﯿﻨﯿﻜﺲ م.م. ﻗﺪ ﺗﺰﯾﺪ ﻣﻦ ﺧﻄﻮرة وﺿﻊ</p><p>ﻣﺘﻼزﻣﺔ اﻟﺴﯿﺮوﺗﻮﻧﯿﻦ )ﻓﻀﻼ اﻧﻈﺮ إﻟﻰ ﻓﻘﺮة&raquo; ﺗﻨﺎول ﺑﻌﺾ اﻷدوﯾﺔ اﻷﺧﺮى.(&laquo;</p><p>&bull; إذا ﻛﻨﺖ ﺗﻌﺎﻧﻰ ﻣﻦ ﻣﺸﺎﻛﻞ ﻓﻰ اﻟﻌﯿﻦ ﻣﺜﻞ ﺑﻌﺾ أﻧﻮاع اﻟﺠﻠﻮﻛﻮﻣﺎ )زﯾﺎدة اﻟﻀﻐﻂ داﺧﻞ اﻟﻌﯿﻦ.(</p><p>&bull; إذا ﻛﺎن ﻟﺪﯾﻚ ﺗﺎرﯾﺦ ﻣﻦ ﺿﻐﻂ اﻟﺪم اﻟﻤﺮﺗﻔﻊ.</p><p>&bull; إذا ﻛﺎن ﻟﺪﯾﻚ ﺗﺎرﯾﺦ ﻣﻦ ﻣﺸﺎﻛﻞ ﺑﺎﻟﻘﻠﺐ.</p><p>&bull; إذا ﻛﺎن ﻟﺪﯾﻚ ﺗﺎرﯾﺦ ﻣﻦ ﻧﻮﺑﺎت اﻟﺼﺮع.</p><p>&bull; إذا ﻛﺎن ﻟﺪﯾﻚ ﺗﺎرﯾﺦ ﻣﻦ اﻧﺨﻔﺎض ﻣﺴﺘﻮى اﻟﺼﻮدﯾﻮم ﺑﺎﻟﺪم )ھﯿﺒﻮﻧﺎﺗﺮﯾﻤﯿﺎ.(</p><p>&bull; &nbsp;إذا ارﺗﻔﻊ ﻣﺴﺘﻮى اﻟﻜﻮﻟﯿﺴﺘﯿﺮول ﺑﺎﻟﺪم ﻟﺪﯾﻚ.</p><p>&bull; إذا أﺧﺒﺮك طﺒﯿﺒﻚ اﻧﻚ ﻣﺼﺎب ﺑﺎﺧﺘﻼل ﻓﻰ ﺿﺮﺑﺎت اﻟﻘﻠﺐ</p><p>&bull; إذا ﻛﺎﻧﺖ ﻟﺪﯾﻚ ﻗﺎﺑﻠﯿﺔ ﻟﺤﺪوث ﻛﺪﻣﺎت أو ﻗﺎﺑﻠﯿﺔ اﻟﻨﺰف ﺑﺴﮭﻮﻟﺔ ) اﺿﻄﺮاﺑﺎت اﻟﻨﺰف(، أو أﻧﻚ ﺗﺘﻨﺎول أدوﯾﺔ أﺧﺮى ﺗﺰﯾﺪ ﻣﻦ</p><p>ﺧﻄﻮرة إﺻﺎﺑﺘﻚ ﺑﺎﻟﻨﺰﯾﻒ ﻣﺜﻞ اﻟﻮارﻓﺎرﯾﻦ اﻟﺬى ﯾﺴﺘﺨﺪم ﻟﻤﻨﻊ ﺗﺠﻠﻂ اﻟﺪم.</p><p>&bull; &nbsp;&nbsp;إذا ﻛﺎن ﻟﺪﯾﻚ ﺗﺎرﯾﺦ أو ﻓﺮد ﻣﻦ أﻓﺮاد أﺳﺮﺗﻚ ﻗﺪ ﻋﺎﻧﻰ ﻣﻦ اﻟﮭﻮس أو اﻻﺿﻄﺮاب اﻟﺜﻨﺎﺋﻲ اﻟﻘﻄﺐ )اﻟﺸﻌﻮر ﺑﺎﻹﺛﺎرة اﻟﻤﻔﺮطﺔ</p><p>أو اﻟﺤﻤﺎﺳﯿﺔ.(</p><p>&bull; إذا ﻛﺎن ﻟﺪﯾﻚ ﺗﺎرﯾﺦ ﻣﻦ اﻟﺴﻠﻮك اﻟﻌﺪواﻧﻰ.</p><p>&nbsp;</p><p>ﻓﯿﻨﯿﻜﺲ م.م. ﻗﺪ ﯾﺘﺴﺒﺐ ﻓﻰ اﻟﺸﻌﻮر ﺑﻌﺪم اﻻرﺗﯿﺎح أو ﻋﺪم اﻟﻘﺪرة ﻋﻠﻰ اﻟﺠﻠﻮس أو اﻟﻮﻗﻮف ﺑﺴﻜﻮن. ﯾﺠﺐ ﻋﻠﯿﻚ إﺧﺒﺎر اﻟﻄﺒﯿﺐ</p><p>إذا ﺣﺪث ﻟﻚ ذﻟﻚ.</p><p>إذا اﻧﻄﺒﻘﺖ ﻋﻠﯿﻚ أي ﻣﻦ ھﺬه اﻟﺤﺎﻻت، ﻓﻀﻼ ﺗﻮاﺻﻞ ﻣﻊ طﺒﯿﺒﻚ ﻗﺒﻞ ﺗﻨﺎول ﻓﯿﻨﯿﻜﺲ م.م.. اﻟﺘﻔﻜﯿﺮ ﻓﻲ اﻻﻧﺘﺤﺎر وازدﯾﺎد ﺳﻮء ﺣﺎﻟﺔ اﻻﻛﺘﺌﺎب أو اﺿﻄﺮاب اﻟﻘﻠﻖ</p><p>إذا ﻛﻨﺖ ﻣﺼﺎﺑﺎ ﺑﺎﻻﻛﺘﺌﺎب و/ أو اﺿﻄﺮاﺑﺎت اﻟﻘﻠﻖ، ﻓﺈﻧﮫ ﻗﺪ ﺗﺮاودك أﺣﯿﺎﻧﺎ ﺑﻌﺾ اﻷﻓﻜﺎر ﻹﯾﺬاء أو ﻗﺘﻞ ﻧﻔﺴﻚ. واﻟﺘﻰ ﻗﺪ ﺗﺰداد ﻋﻨﺪ ﺗﻨﺎوﻟﻚ ﻟﻤﻀﺎدات اﻻﻛﺘﺌﺎب ﻟﻠﻤﺮة اﻷوﻟﻰ، ﺣﯿﺚ أن ھﺬه اﻷدوﯾﺔ ﺗﺴﺘﻐﺮق وﻗﺘﺎ ﻟﻜﻰ ﺗﻌﻤﻞ، ﻋﺎدة ﺣﻮاﻟﻰ أﺳﺒﻮﻋﯿﻦ، ورﺑﻤﺎ</p><p>أﻛﺜﺮ ﻓﻰ ﺑﻌﺾ اﻷﺣﯿﺎن.</p><p>ﻗﺪ ﺗﻜﻮن أﻛﺜﺮ ﻋﺮﺿﺔ ﻟﻠﺘﻔﻜﯿﺮ ھﻜﺬا ﻓﻰ اﻟﺤﺎﻻت اﻻﺗﯿﺔ:</p><p>&bull; إذا ﻛﺎﻧﺖ ﺗﻠﻚ اﻷﻓﻜﺎر ﻋﻦ ﻗﺘﻞ أو إﯾﺬاء ﻧﻔﺴﻚ ﻗﺪ راودﺗﻚ ﻣﻦ ﻗﺒﻞ.</p><p>&bull; إذا ﻛﻨﺖ ﺑﺎﻟﻐﺎ ﺻﻐﯿﺮ اﻟﺴﻦ. ﺣﯿﺚ أن اﻟﻤﻌﻠﻮﻣﺎت ﻣﻦ اﻟﺘﺠﺎرب اﻟﺴﺮﯾﺮﯾﺔ ﺗﻔﯿﺪ ﺑﺰﯾﺎدة ﺧﻄﻮرة ﺳﻠﻮك اﻻﻧﺘﺤﺎر ﻟﺪى اﻟﺒﺎﻟﻐﯿﻦ ﺻﻐﺎر</p><p>اﻟﺴﻦ )أﻗﻞ ﻣﻦ ﻋﻤﺮ ٥٢ ﺳﻨﺔ( اﻟﻤﺼﺎﺑﯿﻦ ﺑﺤﺎﻻت ﻧﻔﺴﯿﺔ وﺗﻌﺮﺿﻮا ﻟﻠﻌﻼج ﺑﻤﻀﺎدات اﻻﻛﺘﺌﺎب.</p><p>إذا راوﺗﻚ أﻓﻜﺎر ﻋﻦ إﯾﺬاء أو ﻗﺘﻞ ﻧﻔﺴﻚ ﻓﻰ أى وﻗﺖ، ﺗﻮاﺻﻞ ﻣﻊ طﺒﯿﺒﻚ أو اذھﺐ ﻓﻮرا إﻟﻰ اﻟﻤﺴﺘﺸﻔﻰ. ﻗﺪ ﯾﻜﻮن ﻣﻦ اﻟﻤﻔﯿﺪ أن ﺗﺨﺒﺮ ﻗﺮﯾﺒﺎ ﻟﻚ أو ﺻﺪﯾﻖ ﻣﻘﺮب إﻟﯿﻚ ﺑﺄﻧﻚ ﻣﺼﺎﺑﺎ ﺑﺎﻻﻛﺘﺌﺎب أو اﺿﻄﺮاب اﻟﻘﻠﻖ، وﺗﺴﺄﻟﮭﻢ ﻟﻘﺮاءة ھﺬه</p><p>اﻟﻨﺸﺮة. ﻗﺪ ﺗﺴﺄﻟﮭﻢ أﯾﻀﺎ ﻟﯿﺨﺒﺮوك إذا ظﻨﻮا أن ﺣﺎﻟﺔ اﻻﻛﺘﺌﺎب أو اﻟﻘﻠﻖ ﻟﺪﯾﻚ ﺗﺰداد ﺳﻮء، أو ﻟﻮ أﻧﮭﻢ ﻗﻠﻘﯿﻦ ﻣﻦ اﻟﺘﻐﯿﺮ ﻓﻰ ﺳﻠﻮﻛﻚ.</p><p>ﻓﻲ ﺣﺎﻟﺔ ﻣﺮﺿﻰ اﻟﺴﻜﺮ: ﻗﺪ ﺗﻀﻄﺮب ﻣﺴﺘﻮﯾﺎت اﻟﺴﻜﺮ ﻓﻲ اﻟﺪم ﻋﻨﺪ ﺗﻨﺎول ﻓﯿﻨﯿﻜﺲ م.م. ، ﻟﺬﻟﻚ ﯾﺘﻮﺟﺐ ﻋﻠﯿﻚ ﺗﻌﺪﯾﻞ ﺟﺮﻋﺔ</p><p>دواء اﻟﺴﻜﺮ اﻟﺘﻲ ﺗﺘﻨﺎوﻟﮭﺎ أﺛﻨﺎء ﺗﻨﺎوﻟﻚ ﻟﻔﯿﻨﯿﻜﺲ م.م.</p><p>ﺟﻔﺎف اﻟﻔﻢ</p><p>&nbsp;</p><p>واﻟﺬى ﻗﺪ ﯾﺰﯾﺪ ﻣﻦ ﺧﻄﻮرة اﻟﺘﺴﻮس، ﻟﺬا ﯾﺠﺐ ﻋﻠﯿﻚ</p><p>&nbsp;</p><p>ﻣﻦ اﻟﻤﺮﺿﻰ اﻟﻤﻌﺎﻟﺠﯿﻦ ﺑﻔﯿﻨﯿﻜﺲ م.م.</p><p>&nbsp;</p><p>ﺟﻔﺎف اﻟﻔﻢ ﻣﺴﺠﻞ ﻓﻰ ٠١%</p><p>اﻻﻋﺘﻨﺎء اﻟﺨﺎص ﺑﻨﻈﺎﻓﺔ أﺳﻨﺎﻧﻚ.</p><p>اﻻﺳﺘﺨﺪام ﻟﻸطﻔﺎل واﻟﺒﺎﻟﻐﯿﻦ أﻗﻞ ﻣﻦ ﺳﻦ ٨١ ﺳﻨﺔ:</p><p>ﻓﯿﻨﯿﻜﺲ م.م. ﻻ ﯾﺴﺘﺨﺪم ﻋﺎدة ﻟﻸطﻔﺎل واﻟﺒﺎﻟﻐﯿﻦ أﻗﻞ ﻣﻦ ﺳﻦ ٨١ ﺳﻨﺔ. أﯾﻀﺎ ﯾﺠﺐ ﻋﻠﯿﻚ أن ﺗﻌﻠﻢ أن اﻟﻤﺮﺿﻰ أﻗﻞ ﺳﻨﺎ ﻣﻦ ٨١ ﺳﻨﺔ أﻛﺜﺮ ﻋﺮﺿﺔ ﻟﻸﻋﺮاض اﻟﺠﺎﻧﺒﯿﺔ، ﻣﺜﻞ ﻣﺤﺎوﻟﺔ اﻻﻧﺘﺤﺎر، أﻓﻜﺎر اﻻﻧﺘﺤﺎر واﻟﻌﺪواﻧﯿﺔ )ﻓﻰ اﻟﻐﺎﻟﺐ ﺳﻠﻮك اﻟﻌﺪاء واﻟﻤﻌﺎرﺿﺔ</p><p>واﻟﻐﻀﺐ( ﻋﻨﺪ ﺗﻌﺮﺿﮭﻢ ﻟﻠﻌﻼج ﺑﮭﺬه اﻟﻤﺠﻤﻮﻋﺔ ﻣﻦ اﻷدوﯾﺔ. ﺑﺎﻟﺮﻏﻢ ﻣﻦ ذﻟﻚ ﻗﺪ ﯾﻠﺠﺄ طﺒﯿﺒﻚ ﻓﻰ ﺑﻌﺾ اﻷﺣﯿﺎن إﻟﻰ وﺻﻒ</p><p>&nbsp;</p><p>إذا ﻗﺎم طﺒﯿﺒﻚ ﺑﻮﺻﻒ ﻓﯿﻨﯿﻜﺲ م.م.</p><p>&nbsp;</p><p>ﻟﻠﻤﺮﺿﻰ اﻷﻗﻞ ﺳﻨﺎ ﻣﻦ ٨١ ﺳﻨﺔ إذا ﻗﺮر أن ذﻟﻚ ﺳﯿﻜﻮن ﻓﻰ ﻣﺼﻠﺤﺘﮭﻢ.</p><p>&nbsp;</p><p>ﻓﯿﻨﯿﻜﺲ م.م.</p><p>&nbsp;</p><p>ﻟﻤﺮﯾﺾ أﻗﻞ ﺳﻨﺎ ﻣﻦ ٨١ ﺳﻨﺔ وأﻧﺖ ﺗﻮد ﻣﻨﺎﻗﺸﺔ ذﻟﻚ، ﻓﻀﻼ ارﺟﻊ إﻟﻰ طﺒﯿﺒﻚ. ﯾﺠﺐ ﻋﻠﯿﻚ إﺧﺒﺎر طﺒﯿﺒﻚ ﻓﻰ ﺣﺎﻟﺔ ظﮭﻮر أو ازدﯾﺎد ﺳﻮء أى ﻣﻦ اﻷﻋﺮاض اﻟﺴﺎﺑﻖ ذﻛﺮھﺎ أﻋﻼه ﻟﻠﻤﺮﺿﻰ اﻷﻗﻞ ﺳﻨﺎ ﻣﻦ ٨١ ﺳﻨﺔ ﻋﻨﺪ ﺗﻨﺎوﻟﮭﻢ ﻟﻔﯿﻨﯿﻜﺲ م.م. أﯾﻀﺎ</p><p>آﺛﺎر اﻟﺴﻼﻣﺔ طﻮﯾﻠﺔ اﻷﺟﻞ ﺑﺸﺄن اﻟﻨﻤﻮ، واﻟﻨﻀﺞ واﻟﺘﻨﻤﯿﺔ اﻟﻤﻌﺮﻓﯿﺔ واﻟﺴﻠﻮﻛﯿﺔ ﻟﻔﯿﻨﯿﻜﺲ م.م. ﻓﻲ ھﺬه اﻟﻔﺌﺔ اﻟﻌﻤﺮﯾﺔ ﻟﻢ ﯾﺘﻢ إﺛﺒﺎﺗﮫ</p><p>ﺣﺘﻰ اﻵن.</p><p>ﺗﻨﺎول أدوﯾﺔ أﺧﺮى</p><p>ﯾﺮﺟﻰ إﺧﺒﺎر اﻟﻄﺒﯿﺐ أو اﻟﺼﯿﺪﻟﻲ إذا ﻛﻨﺖ ﺗﺘﻨﺎول أو ﺗﻨﺎوﻟﺖ ﻣﺆﺧﺮا أي أدوﯾﺔ أﺧﺮى، ﺑﻤﺎ ﻓﻲ ذﻟﻚ اﻷدوﯾﺔ اﻟﺘﻲ ﺗﻢ اﻟﺤﺼﻮل</p><p>ﻋﻠﯿﮭﺎ دون وﺻﻔﺔ طﺒﯿﺔ.</p><p>ﯾﺠﺐ ﻋﻠﻰ طﺒﯿﺒﻚ أن ﯾﻘﺮر ﻣﺎ إذا ﻛﻨﺖ ﯾﻤﻜﻨﻚ ﺗﻨﺎول ﻓﯿﻨﯿﻜﺲ م.م. ﻣﻊ أدوﯾﺔ أﺧﺮى ام ﻻ. ﻻ ﺗﺒﺪأ أو ﺗﺘﻮﻗﻒ ﻋﻦ ﺗﻨﺎول أي أدوﯾﺔ، ﺑﻤﺎ ﻓﻲ ذﻟﻚ ﺗﻠﻚ اﻟﺘﻰ ﯾﺘﻢ ﺷﺮاؤھﺎ دون وﺻﻔﺔ طﺒﯿﺔ واﻻدوﯾﺔ اﻟﻄﺒﯿﻌﯿﺔ واﻟﻌﻼﺟﺎت</p><p>اﻟﻌﺸﺒﯿﺔ، ﻗﺒﻞ ﻣﺮاﺟﻌﺔ طﺒﯿﺒﻚ أو اﻟﺼﯿﺪﻟﻲ.</p><p>&bull; ﯾﺠﺐ أﻻ ﺗﺆﺧﺬ ﻣﺜﺒﻄﺎت أوﻛﺴﯿﺪﯾﺰ أﺣﺎدى اﻷﻣﯿﻦ اﻟﺘﻲ ﺗﺴﺘﺨﺪم ﻟﻌﻼج اﻻﻛﺘﺌﺎب أو ﻣﺮض ﺑﺎرﻛﻨﺴﻮن ﻣﻊ ﻓﯿﻨﯿﻜﺲ م.م. ، أﺧﺒﺮ</p><p>طﺒﯿﺒﻚ إذا ﻛﻨﺖ ﻗﺪ ﺗﻨﺎوﻟﺖ ھﺬه اﻷدوﯾﺔ ﺧﻼل ال ٤١ ﯾﻮم اﻟﺴﺎﺑﻘﺔ. )اﻧﻈﺮ ﻗﺴﻢ &quot;ﻗﺒﻞ أن ﺗﺘﺨﺬ ﻓﯿﻨﯿﻜﺲ م.م.(&quot;.</p><p>&bull; ﻣﺘﻼزﻣﺔ اﻟﺴﯿﺮوﺗﻮﻧﯿﻦ:</p><p>&nbsp;</p><p>ﱠﺪوا&nbsp; ِء اﻟ&nbsp; ُﻤﻀﺎ ﱢد ﻟﻠ ﱡﺬھﺎن ، ﻗﺪ ﺗﺤﺪث ﻣﻊ اﻟﻌﻼج ﺑﻔﯿﻨﻼﻓﺎﻛﺴﯿﻦ، ﻻ ز َﻣﺔُ اﻟﺨﺒﯿﺜَﺔُ ﻟﻠ</p><p>&nbsp;</p><p>ﺣﺎﻟﺔ رﺑﻤﺎ ﺗﮭﺪد اﻟﺤﯿﺎة أوﺗﺴﺒﺐ ﺣﺎﻟﺔ ﺗﺸﺎﺑﮫ اﻟ ُﻤﺘَﻼَ</p><p>ﺳﯿﻤﺎ ﻋﻨﺪﻣﺎ ﯾﺘﻢ ﺗﻨﺎوﻟﮫ ﻣﻊ أدوﯾﺔ أﺧﺮى.</p><p>وﻣﻦ اﻷﻣﺜﻠﺔ ﻋﻠﻰ ھﺬه اﻷدوﯾﺔ ﻣﺎ ﯾﻠﻲ:</p><p>&bull; أدوﯾﺔ اﻟﺘﺮﯾﺒﺘﺎن )اﻟﺘﻲ ﺗﺴﺘﺨﺪم ﻟﻠﺼﺪاع اﻟﻨﺼﻔﻲ(</p><p>&nbsp;</p><p>&bull; اﻷدوﯾﺔ اﻷﺧﺮى ﻟﻌﻼج اﻻﻛﺘﺌﺎب، وﻋﻠﻰ ﺳﺒﯿﻞ اﻟﻤﺜﺎلSSRI،SNRI ، ﺛﻼﺛﯿﺔ اﻟﺤﻠﻘﺎت، أو اﻷدوﯾﺔ اﻟﺘﻲ ﺗﺤﺘﻮي ﻋﻠﻰ اﻟﻠﯿﺜﯿﻮم</p><p>&bull; اﻷدوﯾﺔ اﻟﺘﻲ ﺗﺤﺘﻮي ﻋﻠﻰ ﻟﯿﻨﺰوﻟﯿﺪ، ﻣﻀﺎد ﺣﯿﻮي )اﻟﺘﻲ ﺗﺴﺘﺨﺪم ﻟﻌﻼج اﻻﻟﺘﮭﺎﺑﺎت(</p><p>&bull; اﻷدوﯾﺔ اﻟﺘﻲ ﺗﺤﺘﻮي ﻋﻠﻰ ﻣﻮﻛﻠﻮﺑﻤﯿﺪ، وھﻮ أﺣﺪى ﻣﺜﺒﻄﺎت أوﻛﺴﯿﺪﯾﺰ أﺣﺎدى اﻷﻣﯿﻦ )اﻟﺘﻲ ﺗﺴﺘﺨﺪم ﻟﻌﻼج اﻻﻛﺘﺌﺎب(</p><p>&bull; اﻷدوﯾﺔ اﻟﺘﻲ ﺗﺤﺘﻮي ﻋﻠﻰ ﺳﯿﺒﻮﺗﺮاﻣﯿﻦ )اﻟﺘﻲ ﺗﺴﺘﺨﺪم ﻻﻧﻘﺎص اﻟﻮزن(</p><p>&bull; اﻷدوﯾﺔ اﻟﺘﻲ ﺗﺤﺘﻮي ﺗﺮاﻣﺎدول، اﻟﻔﻨﺘﺎﻧﯿﻞ، ﺗﺎﺑﯿﻨﺘﺎدول، اﻟﺒﯿﺜﯿﺪﯾﻦ، أو ﺑﻨﺘﺎزوﺳﯿﻦ )اﻟﺘﻲ ﺗﺴﺘﺨﺪم ﻟﻌﻼج اﻷﻟﻢ اﻟﺤﺎد(</p><p>&bull; اﻷدوﯾﺔ اﻟﺘﻲ ﺗﺤﺘﻮي ﻋﻠﻰ داﻛﺴﺘﺮوﻣﺜﻮرﻓﻦ )ﺗﺴﺘﺨﺪم ﻟﻌﻼج اﻟﺴﻌﺎل(</p><p>&bull; اﻷدوﯾﺔ اﻟﺘﻲ ﺗﺤﺘﻮي ﻋﻠﻰ اﻟﻤﯿﺜﺎدون )ﺗﺴﺘﺨﺪم ﻟﻌﻼج اﻹدﻣﺎن ﻋﻠﻰ اﻟﻤﺨﺪرات اﻟﻤﻮاد اﻷﻓﯿﻮﻧﯿﺔ أوﻓﻰ ﺣﺎﻻت اﻷﻟﻢ ﺷﺪﯾﺪ(</p><p>&bull; اﻷدوﯾﺔ اﻟﺘﻲ ﺗﺤﺘﻮي ﻋﻠﻰ اﻟﻤﯿﺜﯿﻠﯿﻦ اﻷزرق )اﻟﺘﻲ ﺗﺴﺘﺨﺪم ﻟﻌﻼج ارﺗﻔﺎع ﻣﺴﺘﻮﯾﺎت اﻟﻤﯿﺘﯿﻤﻮﻏﻠﻮﺑﯿﻦ ﻓﻲ اﻟﺪم(</p><p>&bull; اﻟﻤﻨﺘﺠﺎت اﻟﺘﻲ ﺗﺤﺘﻮي ﻋﻠﻰ ﻧﺒﺘﺔ ﺳﺎﻧﺖ ﺟﻮن )ﻋﻼج طﺒﯿﻌﻲ أو ﻋﺸﺒﻲ ﯾﺴﺘﺨﺪم ﻟﻌﻼج اﻻﻛﺘﺌﺎب اﻟﺨﻔﯿﻒ(</p><p>&bull; اﻟﻤﻨﺘﺠﺎت اﻟﺘﻲ ﺗﺤﺘﻮي ﻋﻠﻰ اﻟﺘﺮﺑﺘﻮﻓﺎن )ﺗﺴﺘﺨﺪم ﻟﺒﻌﺾ اﻟﺤﺎﻻت اﻟﻤﺮﺿﯿﺔ ﻣﺜﻞ اﻟﻨﻮم واﻻﻛﺘﺌﺎب(</p><p>&bull; ﻣﻀﺎدات اﻟﺬھﺎن )اﻟﺘﻲ ﺗﺴﺘﺨﺪم ﻟﻌﻼج اﻟﻤﺮض ﻣﻊ أﻋﺮاض ﻣﺜﻞ اﻟﺴﻤﻊ، ورؤﯾﺔ أو ﺗﺤﺴﺲ اﻷﺷﯿﺎء اﻟﺘﻲ ﻟﯿﺴﺖ ﻣﻮﺟﻮدة،</p><p>واﻟﻤﻌﺘﻘﺪات اﻟﺨﺎطﺌﺔ، ارﺗﯿﺎب ﻏﯿﺮ ﻋﺎدي، واﻟﻤﻨﻄﻖ اﻟﻐﯿﺮاﻟﻮاﺿﺢ واﺣﺴﺎس اﻻﻧﺴﺤﺎب(</p><p>وﯾﻤﻜﻦ أن ﺗﺸﻤﻞ ﻋﻼﻣﺎت وأﻋﺮاض ﻣﺘﻼزﻣﺔ اﻟﺴﯿﺮوﺗﻮﻧﯿﻦ ﻣﺰﯾﺞ ﻣﻦ ﻣﺎ ﯾﻠﻲ:</p><p>اﻷرق واﻟﮭﻠﻮﺳﺔ، وﻓﻘﺪان اﻟﺘﻨﺴﯿﻖ، ﺿﺮﺑﺎت اﻟﻘﻠﺐ اﻟﺴﺮﯾﻌﺔ، وزﯾﺎدة درﺟﺔ ﺣﺮارة اﻟﺠﺴﻢ، واﻟﺘﻐﯿﺮات اﻟﺴﺮﯾﻌﺔ ﻓﻲ ﺿﻐﻂ اﻟﺪم،</p><p>وردود اﻟﻔﻌﻞ ﻣﺒﺎﻟﻎ ﻓﯿﮭﺎ، ﻓﺮط ﻧﺸﺎط، واﻹﺳﮭﺎل، واﻟﻐﯿﺒﻮﺑﺔ، واﻟﻐﺜﯿﺎن، واﻟﺘﻘﯿﺆ. ﺣﺪة، ﯾﻤﻜﻦ ﻣﺘﻼزﻣﺔ اﻟﺴﯿﺮوﺗﻮﻧﯿﻦ أن ﺗﺸﺒﮫ اﻟ ُﻤﺘَﻼَ ِز َﻣﺔُ اﻟﺨﺒﯿﺜَﺔُ ﻟﻠ ﱠﺪوا ِء اﻟ ُﻤﻀﺎ ﱢد ﻟﻠ ﱡﺬھﺎن وﯾﻤﻜﻦ أن ﺗﺸﻤﻞ ﻋﻼﻣﺎت ﻣﺰﯾﺞ ﻣﻦ ﺣﻤﻰ، ﺿﺮﺑﺎت اﻟﻘﻠﺐ اﻟﺴﺮﯾﻌﺔ، واﻟﺘﻌﺮق، وﺗﺼﻠﺐ اﻟﻌﻀﻼت ﺷﺪﯾﺪة، واﻻرﺗﺒﺎك، وزﯾﺎدة ﻓﻲ ﺷﻜﻠﮭﺎ اﻷﻛﺜﺮ وأﻋﺮاض ھﺬه اﻟﺤﺎﻟﺔ</p><p>إﻧﺰﯾﻤﺎت اﻟﻌﻀﻼت )ﺗﺤﺪد ﻋﻦ طﺮﯾﻖ ﻓﺤﺺ اﻟﺪم.(</p><p>أﺧﺒﺮ طﺒﯿﺒﻚ ﻓﻮرا، أو ﺗﻮﺟﮫ إﻟﻰ ﻗﺴﻢ اﻟﻄﻮارئ ﻓﻲ أﻗﺮب ﻣﺴﺘﺸﻔﻰ إذا ﻛﻨﺖ ﺗﻌﺘﻘﺪ اﻧﻚ ﻣﺼﺎب ﺑﻤﺘﻼزﻣﺔ اﻟﺴﯿﺮوﺗﻮﻧﯿﻦ.</p><p>ﯾﺠﺐ إﺧﺒﺎر اﻟﻄﺒﯿﺐ إذا ﻛﻨﺖ ﺗﺘﻨﺎول اﻷدوﯾﺔ اﻟﺘﻲ ﯾﻤﻜﻦ أن ﺗﺆﺛﺮ ﻋﻠﻰ ﺿﺮﺑﺎت اﻟﻘﻠﺐ اﻟﺨﺎص ﺑﻚ.</p><p>وﻣﻦ اﻷﻣﺜﻠﺔ ﻋﻠﻰ ھﺬه اﻷدوﯾﺔ ﻣﺎ ﯾﻠﻲ:</p><p>&bull; &nbsp;ُﻣﻀﺎ ﱡد ا &nbsp;ْﺿ &nbsp;ِﻄﺮا &nbsp;ِب اﻟﻨﱠ &nbsp;ْﻈﻢ اﻟﻘﻠﺒﻰ ﻣﺜﻞ ﻛﯿﻨﯿﺪﯾﻦ، اﻷﻣﯿﻮدارون، اﻟﺴﻮﺗﺎﻟﻮل أو ھﯿﺪروﻛﻠﻮرﯾﺪ دوﻓﯿﺘﯿﻠﯿﺪ )اﻟﺘﻲ ﺗﺴﺘﺨﺪم ﻟﻌﻼج</p><p>ﺿﺮﺑﺎت اﻟﻘﻠﺐ ﻏﯿﺮ طﺒﯿﻌﯿﺔ(</p><p>&bull; ﻣﻀﺎدات اﻟﺬھﺎن ﻣﺜﻞ ﺛﯿﻮرﯾﺪازﯾﻦ )اﻧﻈﺮ أﯾﻀﺎ اﻟﺴﯿﺮوﺗﻮﻧﯿﻦ ﻣﺘﻼزﻣﺔ أﻋﻼه(</p><p>&bull; اﻟﻤﻀﺎدات اﻟﺤﯿﻮﯾﺔ ﻣﺜﻞ اﻻرﯾﺜﺮوﻣﯿﺴﯿﻦ أو ﻣﻮﻛﺴﯿﻔﻠﻮﻛﺴﺎﺳﯿﻦ )ﯾﺴﺘﺨﺪم ﻟﻌﻼج اﻻﻟﺘﮭﺎﺑﺎت اﻟﺒﻜﺘﯿﺮﯾﺔ(</p><p>&bull; ﻣﻀﺎدات اﻟﮭﯿﺴﺘﺎﻣﯿﻦ )اﻟﺘﻲ ﺗﺴﺘﺨﺪم ﻟﻌﻼج اﻟﺤﺴﺎﺳﯿﺔ( اﻷدوﯾﺔ اﻟﺘﺎﻟﯿﺔ ﻗﺪ ﺗﺘﻔﺎﻋﻞ أﯾﻀﺎ ﻣﻊ ﻓﯿﻨﯿﻜﺲ م.م وﯾﻨﺒﻐﻲ أن ﺗﺴﺘﺨﺪم ﺑﺤﺬر. ﻣﻦ اﻟﻤﮭﻢ ﺑﺼﻔﺔ ﺧﺎﺻﺔ أن أذﻛﺮ طﺒﯿﺒﻚ أو اﻟﺼﯿﺪﻟﻲ</p><p>إذا ﻛﻨﺖ ﺗﺄﺧﺬ أدوﯾﺔ ﺗﺤﺘﻮي ﻋﻠﻰ:</p><p>&bull; اﻟﻜﯿﺘﻮﻛﻮﻧﺎزول )دواء ﻣﻀﺎد ﻟﻠﻔﻄﺮﯾﺎت(</p><p>&bull; ھﺎﻟﻮﺑﯿﺮﯾﺪول أو رﯾﺴﺒﯿﺮﯾﺪون )ﻟﻌﻼج اﻟﺤﺎﻻت اﻟﻨﻔﺴﯿﺔ(</p><p>&bull; ﻣﯿﺘﻮﺑﺮوﻟﻮل )ﺣﺎﺻﺮات ﺑﯿﺘﺎ ﻟﻌﻼج ارﺗﻔﺎع ﺿﻐﻂ اﻟﺪم واﻣﺮاض اﻟﻘﻠﺐ(</p><p>ﺗﻨﺎول ﻓﯿﻨﯿﻜﺲ م.م. ﻣﻊ اﻟﻄﻌﺎم واﻟﺸﺮاب:</p><p>&nbsp;</p><p>ﺗﺠﻨﺐ ﺗﻨﺎول اﻟﻜﺤﻮل أﺛﻨﺎء ﺗﻨﺎوﻟﻚ</p><p>&nbsp;</p><p>ﻣﻊ اﻟﻄﻌﺎم )اﻧﻈﺮ اﻟﻔﻘﺮة ٣ &raquo;طﺮﯾﻘﺔ اﺳﺘﺨﺪام ﻓﯿﻨﯿﻜﺲ م.م. .(&raquo;</p><p>&nbsp;</p><p>ﯾﺠﺐ ﺗﻨﺎول ﻓﯿﻨﯿﻜﺲ م.م.</p><p>ﻟﻔﯿﻨﯿﻜﺲ م.م.</p><p>اﻟﺤﻤﻞ واﻟﺮﺿﺎﻋﺔ:</p><p>&nbsp;</p><p>ﯾﺠﺐ ﻋﻠﯿﻚ إﺧﺒﺎر طﺒﯿﺒﻚ إذا أﺻﺒﺤﺖ ﺣﺎﻣﻼ، أو ﺗﺤﺎوﻟﻰ أن ﺗﺼﺒﺤﻰ ﺣﺎﻣﻼ. ﯾﺠﺐ ﻋﻠﯿﻚ اﺳﺘﺨﺪام ﻓﯿﻨﯿﻜﺲ م.م. ﻓﻘﻂ ﺑﻌﺪ ﻣﻨﺎﻗﺸﺔ</p><p>اﻟﻔﻮاﺋﺪ اﻟﻤﺤﺘﻤﻠﺔ واﻟﻤﺨﺎطﺮ اﻟﻤﺤﺘﻤﻠﺔ ﻋﻠﻰ اﻟﺠﻨﯿﻦ ﻣﻊ طﺒﯿﺒﻚ.</p><p>&nbsp;</p><p>ﺗﺄﻛﺪى ﻣﻦ إﺧﺒﺎر ﻣﻤﺮﺿﺔ اﻟﺘﻮﻟﯿﺪ و/ أو اﻟﻄﺒﯿﺐ ﺑﺄﻧﻚ ﺗﺨﻀﻌﻰ ﻟﻠﻌﻼج ﺑﻔﯿﻨﯿﻜﺲ م.م. ﻋﻨﺪ اﻻﺳﺘﺨﺪام ﺧﻼل ﻓﺘﺮة اﻟﺤﻤﻞ، اﻷدوﯾﺔ</p><p>اﻟﻤﺸﺎﺑﮭﺔ (SSRIs) ﻗﺪ ﺗﺰﯾﺪ ﻣﻦ ﻣﺨﺎطﺮ ﺣﺎﻟﺔ ﺧﻄﯿﺮة ﻓﻲ اﻷطﻔﺎل، وﺗﺴﻤﻰ ارﺗﻔﺎع ﺿﻐﻂ اﻟﺪم اﻟﺮﺋﻮي اﻟﻤﺴﺘﻤﺮ ﻋﻨﺪ اﻟﻤﻮﻟﻮد</p><p>(PPHN)، ﻣﻤﺎ ﯾﺠﻌﻞ اﻟﻄﻔﻞ ﯾﺘﻨﻔﺲ ﺑﺸﻜﻞ أﺳﺮع، وﯾﺒﺪو ﻣﺰرﻗﺎ. ھﺬه اﻷﻋﺮاض ﺗﺒﺪأ ﻋﺎدة ﺧﻼل ال ٤٢ ﺳﺎﻋﺔ اﻷوﻟﻰ ﺑﻌﺪ</p><p>وﻻدة اﻟﻄﻔﻞ. ﻓﻰ ﺣﺎﻟﺔ ﺣﺪوث ذﻟﻚ ﻟﻄﻔﻠﻚ ﯾﺠﺐ ﻋﻠﯿﻚ اﻻﺗﺼﺎل ﺑﻤﻤﺮﺿﺔ اﻟﺘﻮﻟﯿﺪ و / أو اﻟﻄﺒﯿﺐ ﻓﻮرا.</p><p>&nbsp;</p><p>ﻓﯿﻨﯿﻜﺲ م.م. ﯾﻤﺮ إﻟﻰ ﺣﻠﯿﺐ اﻷم. ﻣﻤﺎ ﻗﺪ ﯾﺴﺒﺐ ﺧﻄﻮرة ﻓﻰ اﻟﺘﺄﺛﯿﺮ ﻋﻠﻰ اﻟﺠﻨﯿﻦ. وﻟﺬﻟﻚ، ﯾﺠﺐ ﻣﻨﺎﻗﺸﺔ ھﺬه اﻟﻤﺴﺄﻟﺔ ﻣﻊ اﻟﻄﺒﯿﺐ،</p><p>وأﻧﮫ / أﻧﮭﺎ ﺳﻮف ﯾﻘﺮر ﻣﺎ إذا ﻛﺎن ﯾﺠﺐ ﻋﻠﯿﻚ اﻟﺘﻮﻗﻒ ﻋﻦ اﻟﺮﺿﺎﻋﺔ اﻟﻄﺒﯿﻌﯿﺔ أو وﻗﻒ اﻟﻌﻼج ﺑﻔﯿﻨﯿﻜﺲ م.م.</p><p>&nbsp;</p><p>ﻛﻨ ِﺖ ﺗﺘﻨﺎوﻟﻲ ھﺬا اﻟﺪواء أﺛﻨﺎء اﻟﺤﻤﻞ، ﻗﺪ ﯾﺼﺎب طﻔﻠﻚ ﺑﺄﻋﺮاض ﻋﻨﺪ وﻻدﺗﮫ ﻛﻌﺪم اﻟﺘﻐﺬﯾﺔ ﺑﺸﻜﻞ ﺻﺤﯿﺢ، ﺑﺎﻹﺿﺎﻓﺔ إﻟﻰ ﺻﻌﻮﺑﺔ ﻓﻲ اﻟﺘﻨﻔﺲ. إذا ﻛﺎن طﻔﻠﻚ ﯾﻌﺎﻧﻲ ﻣﻦ ھﺬه اﻷﻋﺮاض ﻋﻨﺪ وﻻدﺗﮫ وﻛﻨﺖ ﻗﻠﻘﺔ، أﺧﺒﺮى ﺑﻄﺒﯿﺒﻚ و / أو ﻣﺘﺎﺑﻊ اﻟﺤﻤﻞ إذا وﺟﻮد</p><p>اﻟﺨﺎص ﺑﻜﻰ اﻟﺬى ﺳﻮف ﯾﻜﻮن ﻗﺎدر ﻋﻠﻰ ﺗﻘﺪﯾﻢ اﻟﻤﺸﻮرة ﻟﻚ</p><p>&nbsp;</p><p>اﻟﻘﯿﺎدة واﺳﺘﺨﺪام اﻵﻻت</p><p>ﻻ ﺗﻘﻮد أو ﺗﺴﺘﺨﺪم أي أدوات أو آﻻت ﺣﺘﻰ ﺗﻌﺮف ﻛﯿﻔﯿﺔ ﺗﺄﺛﯿﺮ ﻓﯿﻨﯿﻜﺲ م.م. ﻋﻠﯿﻚ.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>ﻗﻢ داﺋﻤﺎ ﺑﺘﻨﺎول ﻓﯿﻨﯿﻜﺲ م.م. ﻛﻤﺎ أﺧﺒﺮك طﺒﯿﺒﻚ اﻟﻤﻌﺎﻟﺞ ﺑﺎﻟﻀﺒﻂ. ﯾﺠﺐ أن ﺗﺤﻘﻖ ﻣﻊ اﻟﻄﺒﯿﺐ أو اﻟﺼﯿﺪﻟﻲ إذا ﻛﻨﺖ ﻏﯿﺮ ﻣﺘﺄﻛﺪ.</p><p>ﺟﺮﻋﺔ اﻟﺒﺪاﯾﺔ اﻟﻤﻮﺻﻰ ﺑﮭﺎ ﻋﺎدة ﻟﻌﻼج اﻻﻛﺘﺌﺎب واﺿﻄﺮاب اﻟﻘﻠﻖ اﻻﺟﺘﻤﺎﻋﻲ ھﻮ ٥٧ ﻣﻠﺠﻢ ﻓﻲ اﻟﯿﻮم اﻟﻮاﺣﺪ. وﯾﻤﻜﻦ رﻓﻊ</p><p>اﻟﺠﺮﻋﺔ ﻣﻦ ﻗﺒﻞ اﻟﻄﺒﯿﺐ ﺗﺪرﯾﺠﯿﺎ، وإذا ﻟﺰم اﻷﻣﺮ، ﺣﺘﻰ ﺗﺼﻞ إﻟﻰ اﻟﺠﺮﻋﺔ اﻟﻘﺼﻮى وھﻰ ٥٧٣ ﻣﻠﺠﻢ ﯾﻮﻣﯿﺎ ﻟﻌﻼج اﻻﻛﺘﺌﺎب. إذا ﻛﻨﺖ ﺗﻌﺎﻟﺞ ﻣﻦ اﺿﻄﺮاب اﻟﮭﻠﻊ، ﺳﻮف ﯾﺒﺪأ طﺒﯿﺒﻚ ﺑﺄﻗﻞ ﺟﺮﻋﺔ )٥.٧٣ ﻣﻠﺠﻢ( و ﺛﻢ ﯾﺰﯾﺪ اﻟﺠﺮﻋﺔ ﺗﺪرﯾﺠﯿﺎ.اﻟﺠﺮﻋﺔ اﻟﻘﺼﻮى</p><p>ﻟﻌﻼج اﺿﻄﺮاب اﻟﻘﻠﻖ اﻻﺟﺘﻤﺎﻋﻲ ھﻲ ٥٢٢ ﻣﻠﺠﻢ ﯾﻮﻣﯿﺎ. ﺗﻨﺎول ﻓﯿﻨﯿﻜﺲ م.م. ﻓﻰ ﻧﻔﺲ اﻟﻮﻗﺖ ﯾﻮﻣﯿﺎ ﻓﻰ اﻟﺼﺒﺎح أو ﻓﻰ اﻟﻤﺴﺎء.ﯾﺠﺐ ﺑﻠﻊ اﻟﻜﺒﺴﻮﻟﺔ ﺑﺸﻜﻞ ﻛﺎﻣﻞ ﻣﻊ ﺳﻮاﺋﻞ دون طﺤﻦ أو</p><p>ﻛﺴﺮ أو ﻓﺘﺢ أو ﻣﻀﻎ.</p><p>ﯾﻨﺼﺢ ﺑﺘﻨﺎول ﻓﯿﻨﯿﻜﺲ م.م. ﻣﻊ اﻷﻛﻞ.</p><p>إذا ﻛﻨﺖ ﺗﻌﺎﻧﻰ ﻣﻦ ﻣﺸﺎﻛﻞ ﻓﻰ اﻟﻜﻠﯿﺔ أو ﻓﻰ اﻟﻜﺒﺪ أﺧﺒﺮ اﻟﻄﺒﯿﺐ ﺣﯿﺚ أن ﺟﺮﻋﺔ ﻓﯿﻨﯿﻜﺲ م.م. ﻗﺪ ﺗﺤﺘﺎج إﻟﻰ ﺗﻌﺪﯾﻞ.</p><p>ﻻ ﺗﺘﻮﻗﻒ ﻋﻦ ﺗﻨﺎول ﻓﯿﻨﯿﻜﺲ م.م. دون اﺳﺘﺸﺎرة اﻟﻄﺒﯿﺐ).اﻧﻈﺮ ﻓﻘﺮة اﻟﺘﻮﻗﻒ ﻋﻦ ﺗﻨﺎول ﻓﯿﻨﯿﻜﺲ م.م.(.</p><p>ﻋﻨﺪ ﺗﻨﺎول ﺟﺮﻋﺔ زاﺋﺪة ﻣﻦ ﻓﯿﻨﯿﻜﺲ م.م:.</p><p>اﺗﺼﻞ ﺑﺎﻟﻄﺒﯿﺐ أو ﺑﺎﻟﺼﯿﺪﻟﻰ ﻓﻮرا اذا ﺗﻨﺎوﻟﺖ ﻛﻤﯿﺔ ﻣﻦ ﻓﯿﻨﯿﻜﺲ م.م. أﻛﺒﺮ ﻣﻤﺎ وﺻﻒ ﻟﻚ اﻟﻄﺒﯿﺐ. ﺗﺘﻔﺎوت أﻋﺮاض اﻟﺠﺮﻋﺔ اﻟﺰاﺋﺪة ﻣﻦ ﻓﯿﻨﯿﻜﺲ م.م. ﻣﻦ زﯾﺎدة ﻓﻰ ﺿﺮﺑﺎت اﻟﻘﻠﺐ إﻟﻰ اﺧﺘﻼف ﻓﻰ ﻣﺴﺘﻮى اﻟﯿﻘﻈﺔ )ﻣﻦ اﻟﻨﻌﺎس إﻟﻰ</p><p>اﻟﻐﯿﺒﻮﺑﺔ( و ﻋﺪم وﺿﻮح اﻟﺮؤﯾﺔ وﻧﻮﺑﺎت اﻟﺼﺮع واﻟﻘﯿﺊ.</p><p>ﻋﻨﺪ ﻧﺴﯿﺎت ﺗﻨﺎول ﺟﺮﻋﺔ ﻓﯿﻨﯿﻜﺲ م.م:. اذا ﻧﺴﯿﺖ ﺗﻨﺎول ﺟﺮﻋﺔ ﻓﯿﻨﯿﻜﺲ م.م. ﺗﻨﺎوﻟﮭﺎ ﻋﻨﺪﻣﺎ ﺗﺘﺬﻛﺮ وﻟﻜﻦ اذا ﺟﺎء ﻣﻮﻋﺪ اﻟﺠﺮﻋﺔ اﻟﺘﺎﻟﯿﺔ ﻻ ﺗﺘﻨﺎول اﻟﺠﺮﻋﺔ اﻟﻤﻨﺴﯿﺔ وﺗﻨﺎول</p><p>اﻟﺠﺮﻋﺔ اﻟﺘﻰ ﺗﻠﯿﮭﺎ ﻓﻰ ﻣﻮﻋﺪھﺎ. ﻻ ﺗﺘﻨﺎول اﻛﺜﺮ ﻣﻦ اﻟﺠﺮﻋﺔ اﻟﯿﻮﻣﯿﺔ اﻟﻤﻮﺻﻮﻓﺔ ﻟﻚ ﻣﻦ اﻟﻄﺒﯿﺐ.</p><p>اﻟﺘﻮﻗﻒ ﻋﻦ ﺗﻨﺎول ﻓﯿﻨﯿﻜﺲ م.م:.</p><p>ﻻ ﺗﺘﻮﻗﻒ ﻋﻦ ﺗﻨﺎول ﻓﯿﻨﯿﻜﺲ م.م. أو ﺗﻘﻠﻞ اﻟﺠﺮﻋﺔ ﺑﺪون اﺳﺘﺸﺎرة اﻟﻄﺒﯿﺐ ﺣﺘﻰ ﻋﻨﺪﻣﺎ ﺗﺘﺤﺴﻦ ﺣﺎﻟﺘﻚ.اذا رأى طﺒﯿﺒﻚ أﻧﻚ ﻻ</p><p>ﺗﺤﺘﺎج ﻓﯿﻨﯿﻜﺲ م.م. ﺳﻮف ﯾﺨﺒﺮك ﺑﺘﻘﻠﯿﻞ اﻟﺠﺮﻋﺔ ﺑﺒﻄﺊ ﻗﺒﻞ أن ﺗﺘﻮﻗﻒ ﻋﻦ ﺗﻨﺎول اﻟﻌﻼج ﺗﻤﺎﻣﺎ. ﯾﺤﺪث أﻋﺮاض ﺟﺎﻧﯿﺔ اذا ﺗﻮﻗﻔﺖ ﻋﻦ ﺗﻨﺎول ﻓﯿﻨﯿﻜﺲ م.م. ﺧﺼﻮﺻﺎ اذا ﺣﺪث ذﻟﻚ ﺑﺼﻮرة ﻣﻔﺎﺟﺌﺔ أو ﻗﻠﻠﺖ اﻟﺠﺮﻋﺔ ﺑﺸﻜﻞ أﺳﺮع ﻣﻦ اﻟﻼزم.وﺗﺘﻔﺎوت ھﺬه اﻷﻋﺮاض ﻣﻦ اﻹرھﺎق واﻟﺪوار و اﻟﺼﺪاع و اﻟﻨﻌﺎس و اﻟﻜﻮاﺑﯿﺲ و ﺟﻔﺎف اﻟﻔﻢ و ﻓﻘﺪان اﻟﺸﮭﯿﺔ و اﻟﻐﺜﯿﺎن و اﻹﺳﮭﺎل واﻟﺘﻮﺗﺮ و اﻟﮭﯿﺎج و اﻻرﺗﺒﺎك و ﺻﻮت رﻧﯿﻦ ﻓﻰ اﻷذن و وﺧﺰ وﻧﺎدرا ﺷﻌﻮر ﺑﺼﺪﻣﺎت ﻛﮭﺮﺑﺎﺋﯿﺔ وﺿﻌﻒ</p><p>وﺗﻌﺮق و ﻧﻮﺑﺎت وأﻋﺮاض ﺗﺸﺒﮫ اﻹﻧﻔﻠﻮﻧﺰا.</p><p>ﺳﻮف ﯾﺮﺷﺪك اﻟﻄﺒﯿﺐ اﻟﻰ ﻛﯿﻔﯿﺔ اﯾﻘﺎف اﻟﺪواء ﺑﺼﻮرة ﺗﺪرﯾﺠﯿﺔ.اذا ﺗﻌﺮﺿﺖ ﻷى ﻣﻦ ھﺬه اﻷﻋﺮاض اﺳﺘﺸﺮ طﺒﯿﺒﻚ.</p><p>اذا ﻛﺎن ﻟﺪﯾﻚ أى ﺳﺆال اﺳﺘﺸﺮ طﺒﯿﺒﻚ.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>ﻣﺜﻞ ﺟﻤﯿﻊ اﻷدوﯾﺔ، ﻓﯿﻨﯿﻜﺲ م.م. ﻗﺪ ﯾﺴﺒﺐ أﻋﺮاض ﺟﺎﻧﺒﯿﺔ، ﻋﻠﻰ اﻟﺮﻏﻢ ﻣﻦ أن اﻟﺠﻤﯿﻊ ﻻ ﯾﺘﻌﺮض ﻟﮭﺎ. إذا ﺗﻌﺮﺿﺖ ﻷي ﻣﻤﺎ ﯾﻠﻲ، ﻻ ﺗﺘﻨﺎول اﻟﻤﺰﯾﺪ ﻣﻦ ﻓﯿﻨﯿﻜﺲ م.م.، أﺧﺒﺮ طﺒﯿﺒﻚ ﻓﻮرا، أو ﺗﻮﺟﮫ إﻟﻰ ﻗﺴﻢ اﻟﻄﻮارئ ﻓﻲ أﻗﺮب</p><p>ﻣﺴﺘﺸﻔﻰ :</p><p>&bull; ﺿﯿﻖ ﻓﻲ اﻟﺼﺪر، و اﻟﺼﻔﯿﺮﻋﻨﺪ اﻟﺘﻨﻔﺲ، ﺻﻌﻮﺑﺔ ﻓﻲ اﻟﺒﻠﻊ أو اﻟﺘﻨﻔﺲ</p><p>&bull; &nbsp;ﺗﻮرم ﻓﻲ اﻟﻮﺟﮫ واﻟﺤﻠﻖ واﻟﯿﺪﯾﻦ، أو اﻟﻘﺪﻣﯿﻦ</p><p>&bull; &nbsp;اﻟﺸﻌﻮر ﺑﺎﻟﺘﻮﺗﺮ أو اﻟﻘﻠﻖ، واﻟﺪوﺧﺔ، اﻟﺨﻔﻘﺎن اﻷﺣﺎﺳﯿﺲ، اﺣﻤﺮار ﻣﻔﺎﺟﺊ ﻓﻰ اﻟﺠﻠﺪ و / أو ﺷﻌﻮر داﻓﺊ</p><p>&bull; اﻟﻄﻔﺢ اﻟﺠﻠﺪي اﻟﺸﺪﯾﺪ، واﻟﺤﻜﺔ، أو اﻟﺸﺮي )ﺑﻘﻊ ﻣﺮﺗﻔﻌﺔ ﻣﻦ اﻟﺠﻠﺪ اﻷﺣﻤﺮ أو اﻟﺸﺎﺣﺐ اﻟﺘﻲ ﻏﺎﻟﺒﺎ ﺗﻜﻮم ﻣﺼﺤﻮﺑﺔ</p><p>ﺑﺤﻜﺔ(</p><p>&bull; ﻋﻼﻣﺎت وأﻋﺮاض ﻣﺘﻼزﻣﺔ اﻟﺴﯿﺮوﺗﻮﻧﯿﻦ واﻟﺘﻲ ﻗﺪ ﺗﺸﻤﻞ اﻷرق واﻟﮭﻠﻮﺳﺔ، وﻓﻘﺪان اﻟﺘﻨﺴﯿﻖ، ﺿﺮﺑﺎت اﻟﻘﻠﺐ</p><p>اﻟﺴﺮﯾﻌﺔ، وزﯾﺎدة درﺟﺔ ﺣﺮارة اﻟﺠﺴﻢ، واﻟﺘﻐﯿﺮات اﻟﺴﺮﯾﻌﺔ ﻓﻲ ﺿﻐﻂ اﻟﺪم، وردود اﻟﻔﻌﻞ ﻣﺒﺎﻟﻎ ﻓﯿﮭﺎ، ﻓﺮط ﻧﺸﺎط،</p><p>واﻹﺳﮭﺎل، واﻟﻐﯿﺒﻮﺑﺔ، واﻟﻐﺜﯿﺎن، واﻟﺘﻘﯿﺆ.</p><p>ﺣﺪة، ﯾﻤﻜﻦ ﻣﺘﻼزﻣﺔ اﻟﺴﯿﺮوﺗﻮﻧﯿﻦ أن ﺗﺸﺒﮫ اﻟ ُﻤﺘَﻼَ &nbsp;ِز َﻣﺔُ اﻟﺨﺒﯿﺜَﺔُ ﻟﻠ ﱠﺪوا ِء اﻟ ُﻤﻀﺎ ﱢد ﻟﻠ ﱡﺬھﺎن وﯾﻤﻜﻦ أن ﺗﺸﻤﻞ ﻋﻼﻣﺎت اﻟﺤﺎﻟﺔ ﻣﺰﯾﺞ ﻣﻦ ﺣﻤﻰ، ﺿﺮﺑﺎت اﻟﻘﻠﺐ اﻟﺴﺮﯾﻌﺔ، واﻟﺘﻌﺮق، وﺗﺼﻠﺐ اﻟﻌﻀﻼت ﺷﺪﯾﺪة، واﻻرﺗﺒﺎك، وزﯾﺎدة ﻓﻲ ﺷﻜﻠﮭﺎ اﻷﻛﺜﺮ وأﻋﺮاض ھﺬه</p><p>إﻧﺰﯾﻤﺎت اﻟﻌﻀﻼت )ﺗﺤﺪد ﻋﻦ طﺮﯾﻖ ﻓﺤﺺ اﻟﺪم.(</p><p>اﻷﻋﺮاض اﻟﺠﺎﻧﺒﯿﺔ اﻷﺧﺮى اﻟﺘﻲ ﯾﺠﺐ أن ﺗﺨﺒﺮ طﺒﯿﺒﻚ ﻋﻨﮭﺎ:</p><p>&bull; &nbsp;اﻟﺴﻌﺎل واﻟﺼﻔﯿﺮ ﻋﻨﺪ اﻟﺘﻨﻔﺲ، وﺿﯿﻖ ﻓﻲ اﻟﺘﻨﻔﺲ وارﺗﻔﺎع ﻓﻲ درﺟﺔ اﻟﺤﺮارة</p><p>&bull; ﺳﻮاد )ﻗﻄﺮاﻧﻰ اﻟﻠﻮن( اﻟﺒﺮاز أو اﻟﺪم ﻓﻲ اﻟﺒﺮاز</p><p>&bull; اﺻﻔﺮار اﻟﺠﻠﺪ أو اﻟﻌﯿﻨﯿﻦ، ﺣﻜﺔ أو ﺑﻮل داﻛﻦ، واﻟﺘﻲ ﻗﺪ ﺗﻜﻮن أﻋﺮاض اﻟﺘﮭﺎب اﻟﻜﺒﺪ )اﻟﺘﮭﺎب اﻟﻜﺒﺪ(</p><p>&bull; &nbsp;أﻋﺮاض ﻗﻠﺒﯿﺔ، ﻣﺜﻞ ﻣﻌﺪل ﺿﺮﺑﺎت اﻟﻘﻠﺐ اﻟﺴﺮﯾﻌﺔ أو ﻋﺪم اﻧﺘﻈﺎم ﺿﺮﺑﺎت اﻟﻘﻠﺐ، وزﯾﺎدة ﺿﻐﻂ اﻟﺪم</p><p>&bull; &nbsp;ﻷﻋﺮاض ﻓﻰ اﻟﻌﯿﻦ، ﻣﺜﻞ ﻋﺪم وﺿﻮح اﻟﺮؤﯾﺔ، واﺗﺴﺎع ﺣﺪﻗﺔ اﻟﻌﯿﻦ</p><p>&bull; &nbsp;أﻋﺮاض ﻋﺼﺒﯿﺔ، ﻣﺜﻞ اﻟﺪوﺧﺔ، و ﺷﻌﻮر اﻟﻮﺧﺰ ﺑﺎﻹﺑﺮ واﻟﺪﺑﺎﺑﯿﺲ، واﺿﻄﺮاب اﻟﺤﺮﻛﺔ أو ﻧﻮﺑﺎت ﺻﺮع أو ﺗﺸﻨﺠﺎت</p><p>&bull; &nbsp;&nbsp;أﻋﺮاض ﻧﻔﺴﯿﺔ، ﻣﺜﻞ ﻓﺮط اﻟﻨﺸﺎط و اﻟﻨﺸﻮة )ﺷﻌﻮر ﻏﯿﺮ طﺒﯿﻌﻰ ﺑﺎﻹﺛﺎرة.((</p><p>&bull; &nbsp;أﻋﺮاض اﻧﺴﺤﺎب )راﺟﻊ ﻗﺴﻢ &quot;ﻛﯿﻔﯿﺔ ﺗﻨﺎول ﻓﯿﻨﯿﻜﺲ م.م.، إذا ﺗﻮﻗﻔﺖ ﻋﻦ ﺗﻨﺎول ﻓﯿﻨﯿﻜﺲ م.م.(&quot;.</p><p>&bull;&nbsp;&nbsp;اﻟﻨﺰﯾﻒ ﻟﻔﺘﺮات طﻮﯾﻠﺔ&nbsp;- إذا ﻗﻤﺖ ﺑﻘﻄﻊ أو ﺟﺮح ﻧﻔﺴﻚ، ﻓﺈﻧﮫ ﻗﺪ ﯾﺴﺘﻐﺮق وﻗﺘﺎ أطﻮل ﻗﻠﯿﻼ ﻣﻦ اﻟﻤﻌﺘﺎد ﻟﺘﻮﻗﻒ اﻟﺪم.&nbsp;</p><p>اﻟﻘﺎﺋﻤﺔ &nbsp;اﻟﻜﺎﻣﻠﺔ ﻟﻸﻋﺮاض اﻟﺠﺎﻧﺒﯿﺔ</p><p><strong>&nbsp;</strong></p><p><strong>ﺷﺎﺋﻌﺔ ﺟﺪا </strong><strong>)</strong><strong>ﯾﺆﺛﺮ ﻋﻠﻰ أﻛﺜﺮ ﻣﻦ ١ ﻓﻲ ﻛﻞ ٠١ أﺷﺨﺎص</strong><strong>(</strong></p><p>&bull; &nbsp;دوﺧﺔ؛ ﺻﺪاع اﻟﺮاس</p><p>&bull; &nbsp;ﻏﺜﯿﺎن؛ ﺟﻔﺎف اﻟﻔﻢ</p><p>&bull; &nbsp;اﻟﺘﻌﺮق )ﺑﻤﺎ ﻓﻲ ذﻟﻚ ﺗﻌﺮق ﻟﯿﻠﻲ(</p><p>اﻟﻤﺸﺘﺮﻛﺔ )ﯾﺆﺛﺮ ﻋﻠﻰ ١-٠١ ﻓﻲ ﻛﻞ ٠٠١ ﺷﺨﺺ(</p><p>&bull; اﻧﺨﻔﺎض اﻟﺸﮭﯿﺔ</p><p>&bull; اﻻرﺗﺒﺎك. اﻟﺸﻌﻮر ﺑﺎﻻﻧﻔﺼﺎل ﻣﻦ ﻧﻔﺴﻚ؛ اﻻﻓﺘﻘﺎر إﻟﻰ اﻟﻨﺸﻮة اﻟﺠﻨﺴﯿﺔ، اﻧﺨﻔﺎض اﻟﺮﻏﺒﺔ اﻟﺠﻨﺴﯿﺔ، اﻟﻌﺼﺒﯿﺔ، اﻷرق؛</p><p>أﺣﻼم ﻏﯿﺮ طﺒﯿﻌﯿﺔ</p><p>&bull; &nbsp;اﻟﻨﻌﺎس؛ اﻟﮭﺰة، ﺷﻌﻮر اﻟﻮﺧﺰ ﺑﺎﻹﺑﺮ واﻟﺪﺑﺎﺑﯿﺲ ؛ زﯾﺎدة ﺗﻮﺗﺮﯾﺔ اﻟﻌﻀﻼت</p><p>&bull; &nbsp;اﺿﻄﺮاﺑﺎت ﺑﺼﺮﯾﺔ ﺑﻤﺎ ﻓﻲ ذﻟﻚ ﻋﺪم وﺿﻮح اﻟﺮؤﯾﺔ. اﺗﺴﺎع ﺣﺪﻗﺔ اﻟﻌﯿﻦ؛ ﻋﺪم ﻗﺪرة اﻟﻌﯿﻦ ﻋﻠﻰ ﺗﻐﯿﺮ اﻟﺘﺮﻛﯿﺰ ﺗﻠﻘﺎﺋﯿﺎ</p><p>ﻣﻦ اﻷﺟﺴﺎم اﻟﺒﻌﯿﺪة إﻟﻰ اﻷﺟﺴﺎم اﻟﻘﺮﯾﺒﺔ</p><p>&bull; &nbsp;اﻟﺮﻧﯿﻦ ﻓﻲ اﻷذﻧﯿﻦ )اﻟﻄﻨﯿﻦ(</p><p>&bull; &nbsp;&nbsp;اﻟﺨﻔﻘﺎن</p><p>&bull; &nbsp;زﯾﺎدة ﻓﻲ ﺿﻐﻂ اﻟﺪم. اﺣﻤﺮار؛</p><p>&bull; &nbsp;اﻟﺘﺜﺎؤب</p><p>&bull; اﻟﺘﻘﯿﺆ؛ اﻹﻣﺴﺎك؛ اﻹﺳﮭﺎل</p><p>&bull; زﯾﺎدة ﻣﺮات اﻟﺘﺒﻮل. ﺻﻌﻮﺑﺎت اﻟﺘﺒﻮل</p><p>&bull; ﻋﺪم اﻧﺘﻈﺎم اﻟﺪورة اﻟﺸﮭﺮﯾﺔ ﻣﺜﻞ زﯾﺎدة اﻟﻨﺰﯾﻒ أو زﯾﺎدة اﻟﻨﺰﯾﻒ اﻟﻐﯿﺮ ﻣﻨﺘﻈﻤﺔ؛ ﻗﺬف او ﻧﺸﻮة ﻏﯿﺮ طﺒﯿﻌﯿﺔ )ذﻛﻮر(؛</p><p>ﻋﺪم اﻟﻘﺪرة ﻋﻠﻰ اﻻﻧﺘﺼﺎب )اﻟﻌﺠﺰ اﻟﺠﻨﺴﻲ(</p><p>&bull; &nbsp;ﺿﻌﻒ )اﻟﻮھﻦ(؛ اﻟﺘﻌﺐ. ﻗﺸﻌﺮﯾﺮة ﺑﺮد</p><p>&bull; زﯾﺎدة اﻟﻜﻮﻟﺴﺘﺮول</p><p>ﻣﻦ ﻏﯿﺮ اﻟﻤﺄﻟﻮف )ﯾﺆﺛﺮ ﻋﻠﻰ ١-٠١ ﻣﻦ ﻛﻞ ٠٠٠١ ﺷﺨﺺ(</p><p>&bull; &nbsp;&nbsp;اﻟﮭﻠﻮﺳﺔ، اﻟﺸﻌﻮر ﺑﺎﻻﻧﻔﺼﺎل ﻋﻦ اﻟﻮاﻗﻊ، اﻹﺛﺎرة، اﻟﻨﺸﻮة اﻟﺠﻨﺴﯿﺔ اﻟﻐﯿﺮ طﺒﯿﻌﯿﺔ )إﻧﺎث(؛ ﻋﺪم وﺟﻮد ﺷﻌﻮر أو ﻋﺎطﻔﺔ،</p><p>اﻟﺸﻌﻮر ﺑﺈﺛﺎرة ﻣﻔﺮطﺔ، ﺣﺮﻛﺔ طﺤﻦ اﻷﺳﻨﺎن</p><p>&bull; &nbsp;ﻋﺪم اﻟﻘﺪرة ﻋﻠﻰ اﻟﺮاﺣﺔ أو ﻋﺪم اﻟﻘﺪرة ﻋﻠﻰ اﻟﺠﻠﻮس أو اﻟﻮﻗﻮف دون ﺣﺮاك. إﻏﻤﺎء؛ ﺣﺮﻛﺎت ﻻ إرادﯾﺔ ﻟﻠﻌﻀﻼت.</p><p>ﺿﻌﻒ اﻟﺘﻨﺴﯿﻖ واﻟﺘﻮازن. ﺗﻐﯿﺮ ﻓﻰ ﺣﺎﺳﺔ اﻟﺘﺬوق</p><p>&bull; ﺳﺮﻋﺔ ﺿﺮﺑﺎت اﻟﻘﻠﺐ. اﻟﺸﻌﻮر ﺑﺎﻟﺪوار )ﺧﺎﺻﺔ ﻋﻨﺪ اﻟﻮﻗﻮف ﺑﺴﺮﻋﺔ ﻛﺒﯿﺮة ﺟﺪا(</p><p>&bull; ﺿﯿﻖ ﺗﻨﻔﺲ</p><p>&bull; ﻗﻲء دﻣﻮى، اﻟﺒﺮاز اﻷﺳﻮد اﻟﻘﻄﺮاﻧﻰ أو دم ﻓﻲ اﻟﺒﺮاز. واﻟﺘﻲ ﯾﻤﻜﻦ أن ﺗﻜﻮن ﻋﻼﻣﺔ ﻋﻠﻰ ﺣﺪوث ﻧﺰﯾﻒ داﺧﻠﻲ</p><p>&bull; ﺗﻮرم ﻋﺎم ﻓﻲ اﻟﺠﻠﺪ ﺧﺎﺻﺔ اﻟﻮﺟﮫ واﻟﻔﻢ واﻟﻠﺴﺎن وﻣﻨﻄﻘﺔ اﻟﺤﻠﻖ أو اﻟﯿﺪﯾﻦ واﻟﻘﺪﻣﯿﻦ و / أو طﻔﺢ ﺟﻠﺪي أو اﻟﺸﺮي،</p><p>ﺣﺴﺎﺳﯿﺔ ﻷﺷﻌﺔ اﻟﺸﻤﺲ، ﻛﺪﻣﺎت، طﻔﺢ؛ ﺗﺴﺎﻗﻂ اﻟﺸﻌﺮ اﻟﻐﯿﺮ طﺒﯿﻌﻲ</p><p>&bull; ﻋﺪم اﻟﻘﺪرة ﻋﻠﻰ اﻟﺘﺒﻮل.</p><p>&bull; زﯾﺎدة اﻟﻮزن؛ ﺧﺴﺎرة اﻟﻮزن</p><p>&nbsp;</p><p>ﻧﺎدرة )ﯾﺆﺛﺮ ﻋﻠﻰ ١-٠١ ﻓﻲ ﻛﻞ ٠٠٠٠١ ﺷﺨﺺ(</p><p>&bull; &nbsp;ﺗﺸﻨﺠﺎت أو ﻧﻮﺑﺎت ﺻﺮع</p><p>&bull; &nbsp;ﻋﺪم اﻟﻘﺪرة ﻋﻠﻰ اﻟﺘﺤﻜﻢ ﻓﻲ اﻟﺘﺒﻮل</p><p>&bull; &nbsp;ﻧﺸﺎط ﻣﻔﺮط، ﺗﺰاﺣﻢ اﻷﻓﻜﺎر واﻧﺨﻔﺎض اﻟﺤﺎﺟﺔ اﻟﻰ اﻟﻨﻮم )اﻟﮭﻮس(</p><p>أﻋﺮاض ﺗﻜﺮارھﺎ ﻏﯿﺮ ﻣﻌﺮوف</p><p>&bull; &nbsp;&nbsp;اﻧﺨﻔﺎض ﻋﺪد اﻟﺼﻔﺎﺋﺢ اﻟﺪﻣﻮﯾﺔ ﻓﻲ اﻟﺪم، ﻣﻤﺎ ﯾﺆدي إﻟﻰ زﯾﺎدة ﺧﻄﺮ ﻛﺪﻣﺎت أواﻟﻨﺰﯾﻒ، اﺿﻄﺮاﺑﺎت اﻟﺪم ﻣﻤﺎ ﻗﺪ ﯾﺆدي&nbsp;</p><p>إﻟﻰ زﯾﺎدة ﺧﻄﺮ اﻟﻌﺪوى.</p><p>&bull; &nbsp;ﺗﻮرم اﻟﻮﺟﮫ أو اﻟﻠﺴﺎن، وﺿﯿﻖ ﻓﻲ اﻟﺘﻨﻔﺲ أو ﺻﻌﻮﺑﺔ ﻓﻲ اﻟﺘﻨﻔﺲ، وﻏﺎﻟﺒﺎ ﻣﻊ طﻔﺢ ﺟﻠﺪي )ھﺬه ﻗﺪ ﺗﻜﻮن أﻋﺮاض ﻓﺮط</p><p>ﺗﺤﺴﺲ ﺧﻄﯿﺮة(</p><p>&bull; ﺗﻨﺎول اﻟﻤﺎء اﻟﺰاﺋﺪ ﻋﻦ اﻟﻄﺒﯿﻌﻰ</p><p>&bull; &nbsp;اﻧﺨﻔﺎض ﻓﻲ ﻣﺴﺘﻮﯾﺎت اﻟﺼﻮدﯾﻮم ﻓﻲ اﻟﺪم</p><p>&bull; اﻟﺘﻔﻜﯿﺮ ﻓﻲ اﻻﻧﺘﺤﺎر واﻟﺴﻠﻮﻛﯿﺎت اﻻﻧﺘﺤﺎرﯾﺔ. وﻗﺪ ﺗﻢ اﻹﺑﻼغ ﻋﻦ ﺣﺎﻻت اﻟﺘﻔﻜﯿﺮ ﻓﻲ اﻻﻧﺘﺤﺎر واﻟﺴﻠﻮﻛﯿﺎت اﻻﻧﺘﺤﺎرﯾﺔ</p><p>ﺧﻼل اﻟﻌﻼج ﺑﺎﻟﻔﯿﻨﻼﻓﺎﻛﺴﯿﻦ أو ﻓﻲ وﻗﺖ ﻣﺒﻜﺮ ﺑﻌﺪ وﻗﻒ اﻟﻌﻼج )اﻧﻈﺮ اﻟﻘﺴﻢ ٢، ﻗﺒﻞ أن ﺗﺘﻨﺎول ﻓﯿﻨﯿﻜﺲ م.م(.</p><p>&bull; اﻻرﺗﺒﺎك واﻟﺤﯿﺮة، ﻛﺜﯿﺮا ﻣﺎ ﯾﻜﻮن ﻣﺼﺤﻮﺑﺎ ﺑﮭﻠﻮﺳﺔ )ھﺬﯾﺎن(؛ اﻟﻌﺪاوة</p><p>&bull; ارﺗﻔﺎع ﻓﻲ درﺟﺔ اﻟﺤﺮارة ﻣﻊ ﺗﺼﻠﺐ اﻟﻌﻀﻼت ، واﻻرﺗﺒﺎك أو اﻹﺛﺎرة، واﻟﺘﻌﺮق، أو إذا ﺗﻌﺮﺿﺖ ﻟﺤﺮﻛﺎت ﻋﻀﻠﯿﺔ واﻟﺘﻲ ﻻ ﯾﻤﻜﻦ اﻟﺴﯿﻄﺮة ﻋﻠﯿﮭﺎ، ﻗﺪ ﺗﻜﻮن ھﺬه أﻋﺮاض ﺧﻄﯿﺮة ﺗﺪﻋﻰ اﻟ ُﻤﺘَﻼَ&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ِز َﻣﺔُ اﻟﺨﺒﯿﺜَﺔُ ﻟﻠ ﱠﺪوا ِء اﻟ ُﻤﻀﺎ ﱢد اﻧﺘﻔﺎﺿﯿﺔ</p><p>ﱡﺬھﺎن، ﻣﺸﺎﻋﺮ ﻓﺮط اﻟﺴﻌﺎدة، واﻟﻨﻌﺎس، ﺣﺮﻛﺔ اﻟﻌﯿﻦ اﻟﺴﺮﯾﻌﺔ اﻟﻤﺴﺘﻤﺮة، اﻟﺤﻤﺎﻗﺎت، واﻷرق، واﻟﺸﻌﻮر ﺑﺄﻧﻚ ﻓﻲ ﺳﻜﺮ، واﻟﺘﻌﺮق أو اﻟﻌﻀﻼت اﻟﻤﺘﺼﻠﺒﺔ، واﻟﺘﻲ ھﻲ أﻋﺮاض ﻣﺘﻼزﻣﺔ اﻟﺴﯿﺮوﺗﻮﻧﯿﻦ، ﺻﻼﺑﺔ، وﺗﺸﻨﺠﺎت و ﻟﻠ ﺣﺎﻟﺔ</p><p>ﺣﺮﻛﺎت اﻟﻌﻀﻼت اﻟﻼ ارادﯾﺔ</p><p>&bull; أﻟﻢ ﺷﺪﯾﺪ ﻓﻲ اﻟﻌﯿﻦ واﻧﺨﻔﺎض أو ﻋﺪم وﺿﻮح اﻟﺮؤﯾﺔ</p><p>&bull; &nbsp;&nbsp;دوار</p><p>&bull; اﻧﺨﻔﺎض ﻓﻲ ﺿﻐﻂ اﻟﺪم. ﺿﺮﺑﺎت اﻟﻘﻠﺐ ﻏﯿﺮ طﺒﯿﻌﯿﺔ وﺳﺮﯾﻌﺔ أو ﺷﺎذة ، ﻣﻤﺎ ﻗﺪ ﯾﺆدي إﻟﻰ اﻹﻏﻤﺎء، ﻧﺰﯾﻒ ﻏﯿﺮ ﻣﺘﻮﻗﻊ، ﻋﻠﻰ ﺳﺒﯿﻞ اﻟﻤﺜﺎل ﻧﺰﯾﻒ اﻟﻠﺜﺔ، دم ﻓﻲ اﻟﺒﻮل أو ﻓﻲ اﻟﻘﻲء، أو ظﮭﻮر ﻛﺪﻣﺎت ﻏﯿﺮ ﻣﺘﻮﻗﻌﺔ أو ﺗﻜﺴﺮ اﻷوﻋﯿﺔ</p><p>اﻟﺪﻣﻮﯾﺔ )ﺗﻜﺴﺮ اﻷوردة(</p><p>&bull; اﻟﺴﻌﺎل واﻟﺼﻔﯿﺮ ﻋﻨﺪ اﻟﺘﻨﻔﺲ، وﺿﯿﻖ ﻓﻲ اﻟﺘﻨﻔﺲ وارﺗﻔﺎع ﻓﻲ درﺟﺔ اﻟﺤﺮارة، واﻟﺘﻲ ھﻲ أﻋﺮاض اﻟﺘﮭﺎب اﻟﺮﺋﺘﯿﻦ</p><p>ﯾﺮﺗﺒﻂ ﻣﻊ زﯾﺎدة ﻓﻲ ﺧﻼﯾﺎ اﻟﺪم اﻟﺒﯿﻀﺎء )ﻓﺮط اﻟﺤﻤﻀﺎت اﻟﺮﺋﻮﯾﺔ(</p><p>&bull; &nbsp;آﻻم ﻓﻲ اﻟﺒﻄﻦ أو اﻟﻈﮭﺮ ﺷﺪﯾﺪة )اﻟﺘﻲ ﯾﻤﻜﻦ أن ﺗﺸﯿﺮ إﻟﻰ وﺟﻮد ﻣﺸﻜﻠﺔ ﺧﻄﯿﺮة ﻓﻲ اﻷﻣﻌﺎء واﻟﻜﺒﺪ واﻟﺒﻨﻜﺮﯾﺎس(</p><p>&bull; &nbsp;اﻟﺤﻜﺔ، واﺻﻔﺮاراﻟﺠﻠﺪ أو اﻟﻌﯿﻨﯿﻦ واﻟﺒﻮل اﻟﺪاﻛﻦ، أو أﻋﺮاض ﺗﺸﺒﮫ اﻻﻧﻔﻠﻮﻧﺰا، واﻟﺘﻲ ھﻲ أﻋﺮاض اﻟﺘﮭﺎب اﻟﻜﺒﺪ،</p><p>ﺗﻐﯿﯿﺮات طﻔﯿﻔﺔ ﻓﻲ ﻣﺴﺘﻮﯾﺎت اﻧﺰﯾﻤﺎت اﻟﻜﺒﺪ ﻓﻰ اﻟﺪم.</p><p>&bull; &nbsp;طﻔﺢ اﻟﺠﻠﺪ، ﻣﻤﺎ ﻗﺪ ﯾﺆدي إﻟﻰ ظﮭﻮر ﺗﻘﺮﺣﺎت ﺷﺪﯾﺪة وﺗﻘﺸﯿﺮ اﻟﺠﻠﺪ، اﻟﺤﻜﺔ، طﻔﺢ ﺟﻠﺪي ﺧﻔﯿﻒ</p><p>&bull; آﻻم ﻓﻲ اﻟﻌﻀﻼت ﻏﯿﺮ ﻣﺒﺮرة، إﯾﻼَم أو ﺿﻌﻒ )اﻧﺤﻼل اﻟﺮﺑﯿﺪات(</p><p>&bull; &nbsp;ﺗﻐﯿﺮ ﻏﯿﺮ طﺒﯿﻌﻰ ﻓﻰ ﻟﺒﻦ اﻟﺜﺪي</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>ﻓﯿﻨﯿﻜﺲ م.م. ﯾﺴﺒﺐ أﺣﯿﺎﻧﺎ أﻋﺮاض ﻏﯿﺮ ﻣﺮﻏﻮب ﻓﯿﮭﺎ و اﻟﺘﻲ ﻗﺪ ﻻ ﺗﻜﻮن ﻋﻠﻰ دراﯾﺔ ﺑﮭﺎ، ﻣﺜﻞ زﯾﺎدة ﺿﻐﻂ اﻟﺪم أو اﺿﻄﺮاب ﺿﺮﺑﺎت اﻟﻘﻠﺐ، ﺗﻐﯿﯿﺮات طﻔﯿﻔﺔ ﻓﻲ ﻣﺴﺘﻮﯾﺎت اﻟﺪم أو إﻧﺰﯾﻤﺎت اﻟﻜﺒﺪ، اﻟﺼﻮدﯾﻮم أو اﻟﻜﻮﻟﯿﺴﺘﺮول، و أﻛﺜﺮ ﻧﺪرة، ﻗﺪ ﯾﺤﺪ ﻓﯿﻨﯿﻜﺲ م.م. ﻣﻦ وظﯿﻔﺔ اﻟﺼﻔﺎﺋﺢ اﻟﺪﻣﻮﯾﺔ ﻓﻲ اﻟﺪم، ﻣﻤﺎ ﯾﺆدي إﻟﻰ زﯾﺎدة ﺧﻄﺮ اﻟﻜﺪﻣﺎت أو اﻟﻨﺰﯾﻒ. ﻟﺬﻟﻚ، ﻗﺪ ﯾﺮﻏﺐ طﺒﯿﺒﻚ ﺑﺈﺟﺮاء</p><p>اﺧﺘﺒﺎرات اﻟﺪم أﺣﯿﺎﻧﺎ، ﺧﺎﺻﺔ إذا ﻛﻨﺖ ﻗﺪ ﺗﻨﺎوﻟﺖ ﻓﯿﻨﯿﻜﺲ م.م. ﻟﻔﺘﺮة طﻮﯾﻠﺔ.</p><p>&nbsp;</p><p>إذا أﺻﺒﺢ أى ﻣﻦ اﻷﻋﺮاض اﻟﺠﺎﻧﺒﯿﺔ ﺧﻄﯿﺮا، أو إذا ﻻﺣﻈﺖ أي أﻋﺮاض ﺟﺎﻧﺒﯿﺔ ﻏﯿﺮ اﻟﻤﺬﻛﻮرة ﻓﻲ ھﺬه اﻟﻨﺸﺮة، ﯾﺮﺟﻰ إﺧﺒﺎر</p><p>اﻟﻄﺒﯿﺐ أو اﻟﺼﯿﺪﻟﻲ.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>اﺣﻔﻆ ﺑﻌﯿﺪا ﻋﻦ ﻣﺘﻨﺎول اﻷطﻔﺎل.</p><p>ﻻ ﺗﺴﺘﺨﺪم ﻓﯿﻨﯿﻜﺲ م.م. ﺑﻌﺪ اﻧﺘﮭﺎء اﻟﺼﻼﺣﯿﺔ اﻟﻤﺬﻛﻮرة ﻋﻠﻰ اﻟﻌﻠﺒﺔ.</p><p>اﻧﺘﮭﺎء اﻟﺼﻼﺣﯿﺔ ﯾﺮﻣﺰ إﻟﻰ اﺧﺮ ﯾﻮم ﻓﻰ اﻟﺸﮭﺮ اﻟﻤﺬﻛﻮر ﻋﻠﻰ اﻟﻌﻠﺒﺔ.</p><p>اﺣﻔﻆ ﻓﻰ درﺟﺔ ﺣﺮارة ﺗﺤﺖ ٠٣ درﺟﺔ. ﻻ ﯾﻨﺒﻐﻰ اﻟﺘﺨﻠﺺ ﻣﻦ اﻷدوﯾﺔ ﻣﻊ ﻣﯿﺎه اﻟﺼﺮف أو ﻣﻊ اﻟﻨﻔﺎﯾﺎت اﻟﻤﻨﺰﻟﯿﺔ.اﺳﺎل اﻟﺼﯿﺪﻟﻰ ﻋﻦ ﻛﯿﻔﯿﺔ اﻟﺘﺨﻠﺺ ﻣﻦ اﻷدوﯾﺔ اﻟﻐﯿﺮ</p><p>ﻣﺴﺘﺨﺪﻣﺔ.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>اﻟﻤﺎده اﻟﻔﻌﺎﻟﮫ ھﻰ ﻓﯿﻨﻼﻓﺎﻛﺴﯿﻦ.</p><p>ﻛﻞ ﻛﺒﺴﻮﻟﺔ ﺻﻠﺒﺔ ﻣﻤﺘﺪة اﻟﻤﻔﻌﻮل ﺗﺤﺘﻮى ﻋﻠﻰ ٥.٧٣ ﻣﻠﺠﻢ و ٥٧ ﻣﻠﺠﻢ و ٠٥١ ﻣﻠﺠﻢ ﻣﻦ ﻓﯿﻨﯿﻜﺲ م.م.</p><p>ھﯿﺪروﻛﻠﻮراﯾﺪ.</p><p>اﻟﻤﻜﻮﻧﺎت اﻷﺧﺮى ھﻰ :</p><p>37.5 ﻣﻠﺠﻢ ﻛﺒﺴﻮﻻت ﺻﻠﺒﺔ ﻣﻤﺘﺪة اﻟﻤﻔﻌﻮل :</p><p>&nbsp;</p><p>و ﺻﻮدﯾﻮم ﻟﻮرﯾﻞ ﺳﻠﻔﺎت</p><p>&nbsp;</p><p>٠٠١</p><p>&nbsp;</p><p>ﺑﻮدرة ﯾﻮدراﺟﯿﺖ أر أس</p><p>&nbsp;</p><p>٠٠١ م(</p><p>&nbsp;</p><p>ھﯿﺒﺮوﻣﯿﻠﻠﻮز )ﻣﯿﺜﻮﺳﯿﻞ ك</p><p>&nbsp;</p><p>ﺗﺤﺘﻮى اﻟﻜﺒﺴﻮﻟﺔ ﻋﻠﻰ :</p><p>&nbsp;</p><p>&nbsp;</p><p>و ﻛﺤﻮل إﯾﺰوﺑﺮوﺑﯿﻞ.</p><p>&nbsp;</p><p>وﺳﺘﯿﺎرﯾﺖ ﻣﺎﻏﻨﺴﯿﻮم و إﺛﺎﻧﻮل.</p><p>اﻟﻐﻼف : ﯾﻮدراﺟﯿﺖ إى ٥.٢١</p><p>&nbsp;</p><p>ﻗﺸﺮة اﻟﻜﺒﺴﻮﻟﺔ : ﺗﯿﺘﺎﻧﯿﻮم ﺛﻨﺎﺋﻰ اﻷوﻛﺴﯿﺪ إى ١٧١ و ﺟﯿﻼﺗﯿﻦ.</p><p>٥٧ ﻣﻠﺠﻢ ﻛﺒﺴﻮﻻت ﺻﻠﺒﺔ ﻣﻤﺘﺪة اﻟﻤﻔﻌﻮل :</p><p>&nbsp;</p><p>و ﺻﻮدﯾﻮم ﻟﻮرﯾﻞ ﺳﻠﻔﺎت</p><p>&nbsp;</p><p>٠٠١</p><p>&nbsp;</p><p>ﺑﻮدرة ﯾﻮدراﺟﯿﺖ أر أس</p><p>&nbsp;</p><p>٠٠١ م(</p><p>&nbsp;</p><p>ھﯿﺒﺮوﻣﯿﻠﻠﻮز )ﻣﯿﺜﻮﺳﯿﻞ ك</p><p>&nbsp;</p><p>ﺗﺤﺘﻮى اﻟﻜﺒﺴﻮﻟﺔ ﻋﻠﻰ :</p><p>وﺳﺘﯿﺎرﯾﺖ ﻣﺎﻏﻨﺴﯿﻮم.</p><p>&nbsp;</p><p>اﻟﻐﻼف : ﯾﻮدراﺟﯿﺖ إى ٠٠١.</p><p>ﻗﺸﺮة اﻟﻜﺒﺴﻮﻟﺔ : ﺗﯿﺘﺎﻧﯿﻮم ﺛﻨﺎﺋﻰ اﻷوﻛﺴﯿﺪ إى ١٧١ و أوﻛﺴﯿﺪ اﻟﺤﺪﯾﺪ )أﺣﻤﺮ( إى ٢٧١ و ﺟﯿﻼﺗﯿﻦ.</p><p>٠٥١ ﻣﻠﺠﻢ ﻛﺒﺴﻮﻻت ﺻﻠﺒﺔ ﻣﻤﺘﺪة اﻟﻤﻔﻌﻮل :</p><p>&nbsp;</p><p>و ﺻﻮدﯾﻮم ﻟﻮرﯾﻞ ﺳﻠﻔﺎت</p><p>&nbsp;</p><p>٠٠١</p><p>&nbsp;</p><p>ﺑﻮدرة ﯾﻮدراﺟﯿﺖ أر أس</p><p>&nbsp;</p><p>٠٠١ م(</p><p>&nbsp;</p><p>ھﯿﺒﺮوﻣﯿﻠﻠﻮز )ﻣﯿﺜﻮﺳﯿﻞ ك</p><p>&nbsp;</p><p>ﺗﺤﺘﻮى اﻟﻜﺒﺴﻮﻟﺔ ﻋﻠﻰ :</p><p>وﺳﺘﯿﺎرﯾﺖ ﻣﺎﻏﻨﺴﯿﻮم.</p><p>&nbsp;</p><p>اﻟﻐﻼف : ﯾﻮدراﺟﯿﺖ إى ٠٠١.</p><p>ﻗﺸﺮة اﻟﻜﺒﺴﻮﻟﺔ : ﺗﯿﺘﺎﻧﯿﻮم ﺛﻨﺎﺋﻰ اﻷوﻛﺴﯿﺪ إى ١٧١ و ارﯾﺜﺮوﺳﯿﻦ إى ٧٢١ و اﻧﺪﯾﺠﻮ ﻛﺎرﻣﯿﻦ إى ٢٣١ و ﺟﯿﻼﺗﯿﻦ.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>ﻛﺒﺴﻮﻻت ﺻﻠﺒﺔ ﻣﻤﺘﺪة اﻟﻤﻔﻌﻮل: ﻛﺒﺴﻮﻻت ﺑﯿﻀﺎء إﻟﻰ ﺑﯿﻀﺎء ﻣﻌﺘﻤﮫ ﺣﺠﻢ ٠ ﻣﻦ اﻟﺠﯿﻼﺗﯿﻦ اﻟﺼﻠﺐ ﺗﺤﺘﻮي ﻋﻠﻲ ٥.٧٣ ﻣﻠﺠﻢ ﻓﯿﻨﻼﻓﺎﻛﺴﯿﻦ. ٥٧ ﻣﻠﺠﻢ ﻋﻠﻲ ﺗﺤﺘﻮي ﻣﻦ اﻟﺠﯿﻼﺗﯿﻦ اﻟﺼﻠﺐ ﺣﺠﻢ ٠ ﻓﻠﯿﺶ ﻣﻌﺘﻤﮫ ﻛﺒﺴﻮﻻت ٥٧ﻣﻠﺠﻢ ﻛﺒﺴﻮﻻت ﺻﻠﺒﺔ ﻣﻤﺘﺪة اﻟﻤﻔﻌﻮل: ﻓﯿﻨﻼﻓﺎﻛﺴﯿﻦ. ٠٥١ﻣﻠﺠﻢ ﻛﺒﺴﻮﻻت ﺻﻠﺒﺔ ﻣﻤﺘﺪة اﻟﻤﻔﻌﻮل: ﻛﺒﺴﻮﻻت ﻗﺮزﻣﯿﺔ ﻣﻌﺘﻤﮫ ﺣﺠﻢ ٠٠ ﻣﻦ اﻟﺠﯿﻼﺗﯿﻦ اﻟﺼﻠﺐ ﺗﺤﺘﻮي ﻋﻠﻰ ٠٥١ ﻣﻠﺠﻢ ﻓﯿﻨﻼﻓﺎﻛﺴﯿﻦ. ﺣﺠﻢ اﻟﻌﺒﻮة: ٢ ﺷﺮﯾﻂ ﻣﻜﻮن ﻣﻦ ٧ ﻛﺒﺴﻮﻻت.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p><strong>إﻧﺘﺎج اﻟﺪواﺋﯿﺔ ﻣﺼﻨﻊ اﻷدوﯾﺔ ﺑﺎﻟﻘﺼﯿﻢ، اﻟﺸﺮﻛﺔ اﻟﺴﻌﻮدﯾﺔ ﻟﻠﺼﻨﺎﻋﺎت اﻟﺪواﺋﯿﺔ واﻟﻤﺴﺘﻠﺰﻣﺎت اﻟﻄﺒﯿﺔ، اﻟﻤﻤﻠﻜﺔ اﻟﻌﺮﺑﯿﺔ اﻟﺴﻌﻮدﯾﺔ.</strong></p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            ﺗﻢ اﻟﻤﻮاﻓﻘﺔ ﻋﻠﻰ ھﺬه اﻟﻨﺸﺮة ﺑﺘﺎرﯾﺦ: دﯾﺴﻤﺒﺮ ٥١٠٢
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                [Venex] 37.5 mg hard prolonged-release capsules.
[Venex] 75 mg hard prolonged-release capsules. 
[Venex] 150 mg hard prolonged-release capsules.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                37.5 mg prolonged-release capsules, hard:a white opaque-white opaque size 0 hard gelatin capsules containing 37.5 mg Venlafaxine.

75 mg prolonged-release capsules, hard: flesh opaque size 0 hard gelatin capsules containing 75 mgVenlafaxine.

150 mg prolonged-release capsules, hard: scarlet opaque size 00 hard gelatin capsules containing 150 mg Venlafaxine.

For a full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Prolonged-release capsule, hard.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><em>4.1 Therapeutic indications</em></strong></p><p>Treatment of major depressive episodes.</p><p>&nbsp;</p><p>For prevention of recurrence of major depressive episodes.</p><p>&nbsp;</p><p>Treatment of social anxiety disorder.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Major depressive episodes</strong></p><p>&nbsp;</p><p>The recommended starting dose for prolonged-release venlafaxine is 75 mg given once daily. Patients not responding to the initial 75 mg/day dose may benefit from dose increases up to a maximum dose of 375 mg/day. Dosage increases can be made at intervals of 2 weeks or more. If clinically warranted due to symptom severity, dose increases can be made at more frequent intervals, but not less than 4 days.</p><p>&nbsp;</p><p>Because of the risk of dose-related adverse effects, dose increments should be made only after a clinical evaluation (see section 4.4). The lowest effective dose should be maintained.</p><p>&nbsp;</p><p>&nbsp;</p><p>Patients should be treated for a sufficient period of time, usually several months or longer. Treatment should be reassessed regularly on a case-by-case basis. Longer-term treatment may also be appropriate for prevention of recurrence of major depressive episodes (MDE). In most of the cases, the recommended dose in prevention of recurrence of MDE is the same as the one used during the current episode.</p><p>&nbsp;</p><p>Antidepressive medicinal products should continue for at least six months following remission The dose range is 150 to 600 mg per day given in either two or three divided doses.</p><p>&nbsp;</p><p><strong>Social anxiety disorder</strong></p><p>&nbsp;</p><p>The recommended dose for prolonged-release venlafaxine is 75 mg given once daily. There is no evidence that higher doses confer any additional benefit.</p><p>&nbsp;</p><p>&nbsp;</p><p>However, in individual patients not responding to the initial 75 mg/day, increases up to a maximum dose of 225 mg/day may be considered. Dosage increases can be made at intervals of 2 weeks or more.</p><p>&nbsp;</p><p>&nbsp;</p><p>Because of the risk of dose-related adverse effects, dose increments should be made only after a clinical evaluation (see section 4.4). The lowest effective dose should be maintained.</p><p>&nbsp;</p><p>&nbsp;</p><p>Patients should be treated for a sufficient period of time, usually several months or longer. Treatment should be reassessed regularly, on a case-by-case basis.</p><p>&nbsp;</p><p><strong>Use in elderly patients</strong></p><p>&nbsp;</p><p>No specific dose adjustments of venlafaxine are considered necessary based on patient age alone. However, caution should be exercised in treating the elderly (e.g., due to the possibility</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>of renal impairment, the potential for changes in neurotransmitter sensitivity and affinity occurring with aging). The lowest effective dose should always be used, and patients should be carefully monitored when an increase in the dose is required.</p><p>&nbsp;</p><p><strong>Use in children and adolescents under the age of 18 years</strong></p><p>&nbsp;</p><p>Venlafaxine is not recommended for use in children and adolescents.</p><p>&nbsp;</p><p>&nbsp;</p><p>Controlled clinical studies in children and adolescents with major depressive disorder failed to demonstrate efficacy and do not support the use of venlafaxine in these patients (see sections 4.4 and 4.8).</p><p>&nbsp;</p><p>&nbsp;</p><p>The efficacy and safety of venlafaxine for other indications in children and adolescents under the age of 18 have not been established.</p><p>&nbsp;</p><p><strong>Use in patients with hepatic impairment</strong></p><p>&nbsp;</p><p>In patients with mild and moderate hepatic impairment, in general a 50% dose reduction should be considered. However, due to inter-individual variability in clearance, individualisation of dosage may be desirable.</p><p>&nbsp;</p><p>There are limited data in patients with severe hepatic impairment. Caution is advised, and a dose reduction by more than 50% should be considered. The potential benefit should be weighed against the risk in the treatment of patients with severe hepatic impairment.</p><p>&nbsp;</p><p><strong>Use in patients with renal impairment</strong></p><p>&nbsp;</p><p>Although no change in dosage is necessary for patients with glomerular filtration rate (GFR) between</p><p>&nbsp;</p><p>30-70 ml/minute, caution is advised. For patients that require haemodialysis and in patients with severe renal impairment (GFR &lt; 30 ml/min), the dose should be reduced by 50%. Because of inter-individual variability in clearance in these patients, individualisation of dosage may be desirable.</p><p>&nbsp;</p><p><strong>Withdrawal symptoms seen on discontinuation of venlafaxine</strong></p><p>&nbsp;</p><p>Abrupt discontinuation should be avoided. When stopping treatment with venlafaxine, the dose should be gradually reduced over a period of at least one to two weeks in order to reduce the risk of withdrawal reactions (see sections 4.4 and 4.8). If intolerable symptoms occur following a decrease in the dose or upon discontinuation of treatment, then resuming the previously</p><p>&nbsp;</p><p>prescribed dose may be considered. Subsequently, the physician may continue decreasing the dose, but at a more gradual rate.</p><p>&nbsp;</p><p>For oral use.</p><p>It is recommended that venlafaxine prolonged-release capsules be taken with food, at approximately the same time each day. Capsules must be swallowed whole with fluid and not divided, crushed, chewed, or dissolved.</p><p>Patients treated with venlafaxine immediate-release tablets may be switched to venlafaxine prolonged- release capsules at the nearest equivalent daily dosage. For example, venlafaxine immediate-release tablets 37.5 mg twice daily may be switched to venlafaxine prolonged-release capsules 75 mg once daily. Individual dosage adjustments may be necessary.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients.

Concomitant treatment with irreversible monoamine oxidase inhibitors (MAOIs) is contraindicated due to the risk of serotonin syndrome with symptoms such as agitation, tremor and hyperthermia. Venlafaxine must not be initiated for at least 14 days after discontinuation of treatment with an irreversible MAOI.

Venlafaxine must be discontinued for at least 7 days before starting treatment with an irreversible MAOI (see sections 4.4 and 4.5).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Suicide/suicidal thoughts or clinical worsening</strong></p><p>&nbsp;</p><p>Depression is associated with an increased risk of suicidal thoughts, self-harm and suicide (suicide- related events). This risk persists until significant remission occurs. As improvement may not occur during the first few weeks or more of treatment, patients should be closely monitored until such improvement occurs. It is general clinical experience that the risk of suicide may increase in the early stages of recovery.</p><p>&nbsp;</p><p>Other psychiatric conditions for which venlafaxine is prescribed can also be associated with an increased risk of suicide-related events. In addition, these conditions may be co-morbid with major depressive disorder. The same precautions observed when treating patients</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>with major depressive disorder should therefore be observed when treating patients with other psychiatric disorders.</p><p>&nbsp;</p><p>&nbsp;</p><p>Patients with a history of suicide-related events, or those exhibiting a si gnificant degree of suicidal ideation prior to commencement of treatment, are known to be at greater risk of suicidal thoughts or suicide attempts, and should receive careful monitoring during treatment. A meta-analysis of placebo- controlled clinical trials of antidepressant drugs in adult patients with psychiatric disorders showed an increased risk of suicidal behaviour with antidepressants compared to placebo in patients less than 25 years old.</p><p>&nbsp;</p><p>Close supervision of patients, and in particular those at high risk, should accompany drug therapy, especially in early treatment and following dose changes. Patients (and caregivers of patients) should be alerted about the need to monitor for any clinical worsening, suicidal behaviour or thoughts and unusual changes in behaviour, and to seek medical advice immediately if these symptoms present</p><p>&nbsp;</p><p><strong>Use in children and adolescents under 18 years of age</strong></p><p>&nbsp;</p><p>Venex XR sh ould not be used in the treatment of children and adolescents under the age of 18 years. Suicide-related behaviours (suicide attempt and suicidal thoughts) and hostility (predominantly aggression, oppositional behaviour and anger) were more frequently observed in clinical trials among children and adolescents treated with antidepressants compared to those treated with placebo. If, based on clinical need, a decision to treat is nevertheless taken, the patient should be carefully monitored for the appearance of suicidal symptoms. In addition, long-term safety data in children and adolescents concerning growth, maturation and cognitive and behavioural development are lacking.</p><p>&nbsp;</p><p><strong>Serotonin syndrome</strong></p><p><strong>&nbsp;</strong></p><p>Serotonin syndrome in its most severe form, can resemble NMS, which includes hyperthermia, muscle rigidity, autonomic instability with possible rapid fluctuation of vital signs and mental status changes.</p><p>If concomitant treatment with venlafaxine and other agents that may affect the serotonergic and/or dopaminergic neurotransmitter systems is clinically warranted, careful observation of</p><p>the patient is advised, particularly during treatment initiation and dose increases.</p><p>The concomitant use of venlafaxine with serotonin precursors (such as tryptophan</p><p>supplements) is not recommended.</p><p>&nbsp;</p><p>&nbsp;</p><p>As with other serotonergic agents, serotonin syndrome, a potentially life-threatening condition, may occur with venlafaxine treatment, particularly with concomitant use of other agents, such as MAO- inhibitors, that may affect the serotonergic neurotransmitter systems (see sections 4.3 and 4.5).</p><p>&nbsp;</p><p>Serotonin syndrome symptoms may include mental status changes (e.g., agitation, hallucinations, coma), autonomic instability (e.g., tachycardia, labile blood pressure, hyperthermia), neuromuscular aberrations (e.g., hyperreflexia, incoordination) and/or gastrointestinal symptoms (e.g., nausea, vomiting, diarrhoea).</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Narrow-angle glaucoma</strong></p><p>&nbsp;</p><p>Mydriasis may occur in association with venlafaxine. It is recommended that patients with raised intraocular pressure or patients at risk for acute narrow-angle glaucoma (angle-closure glaucoma) be closely monitored.</p><p>&nbsp;</p><p><strong>Blood pressure</strong></p><p>&nbsp;</p><p>Dose-related increases in blood pressure have been commonly reported with venlafaxine. In some cases, severely elevated blood pressure requiring immediate treatment has been reported in postmarketing experience. All patients should be carefully screened for high blood pressure and pre- existing hypertension should be controlled before initiation of treatment. Blood pressure should be reviewed periodically, after initiation of treatment and after dose increases. Caution should be exercised in patients whose underlying conditions might be compromised by increases in blood pressure, e.g., those with impaired cardiac function.</p><p>&nbsp;</p><p><strong>Heart rate</strong></p><p>&nbsp;</p><p>Increases in heart rate can occur, particularly with higher doses. Caution should be exercised in patients whose underlying conditions might be compromised by increases in heart rate.</p><p>&nbsp;</p><p><strong>Cardiac disease and risk of arrhythmia</strong></p><p><strong>&nbsp;</strong></p><p>in postmarketing experience, cases of QTc prolongation, Torsade de Pointes (TdP),</p><p>ventricular tachycardia, and fatal cardiac arrhythmias have been reported with the use of venlafaxine, especially in overdose or in patients with other risk factors for QTc prolongation/TdP. The balance of risks and benefits should be considered before prescribing venlafaxine to patients at high risk of serious cardiac arrhythmia or QTc prolongation.</p><p>&nbsp;</p><p>Venlafaxine has not been evaluated in patients with a recent history of myocardial infarction or unstable heart disease. Therefore, it should be used with caution in these patients.</p><p>&nbsp;</p><p>In postmarketing experience, fatal cardiac arrhythmias have been reported with the use of venlafaxine, especially in overdose. The balance of risks and benefits should be considered before prescribing venlafaxine to patients at high risk of serious cardiac arrhythmia.</p><p>&nbsp;</p><p><strong>Diabetes</strong><strong> </strong></p><p>In patients with diabetes, treatment with an SSRI or venlafaxine may alter glycaemic control. Insulin and/or oral antidiabetic dosage may need to be adjusted.</p><p>&nbsp;</p><p><strong>Convulsions</strong></p><p>&nbsp;</p><p>Convulsions may occur with venlafaxine therapy. As with all antidepressants, venlafaxine should be introduced with caution in patients with a history of convulsions, and concerned patients should be closely monitored. Treatment should be discontinued in any patient who develops seizures.</p><p>&nbsp;</p><p><strong>Hyponatraemia</strong></p><p>&nbsp;</p><p>Cases of hyponatraemia and/or the Syndrome of Inappropriate Antidiuretic Hormone (SIADH) secretion may occur with venlafaxine. This has most frequently been reported in volume-depleted or dehydrated patients. Elderly patients, patients taking diuretics, and patients who are otherwise volume- depleted may be at greater risk for this event.</p><p>&nbsp;</p><p><strong>Abnormal bleeding</strong></p><p>&nbsp;</p><p>Medicinal products that inhibit serotonin uptake may lead to reduced platelet function. The risk of skin and mucous membrane bleeding, including gastrointestinal haemorrhage, may be increased in patients taking venlafaxine. As with other serotonin-reuptake inhibitors, venlafaxine should be used cautiously in patients predisposed to bleeding, including patients on anticoagulants and platelet inhibitors.</p><p>&nbsp;</p><p><strong>Drug-Laboratory Test Interactions</strong></p><p>False-positive urine immunoassay screening tests for phencyclidine (PCP) and amphetamine have been reported in patients taking venlafaxine. This is due to lack of specificity of the screening tests. False positive test results may be expected for several days following discontinuation of venlafaxine therapy. Confirmatory tests, such as gas chromatography/mass spectrometry, will distinguish venlafaxine from PCP and amphetamine</p><p>&nbsp;</p><p><strong>Serum cholesterol</strong></p><p>&nbsp;</p><p>Clinically relevant increases in serum cholesterol were recorded in 5.3% of venlafaxine-treated patients and 0.0% of placebo-treated patients treated for at least 3 months in placebo-controlled clinical trials. Measurement of serum cholesterol levels should be considered during long-term treatment.</p><p>&nbsp;</p><p><strong>Co-administration with weight loss agents</strong></p><p>&nbsp;</p><p>The safety and efficacy of venlafaxine therapy in combination with weight loss agents, including phentermine, have not been established. Co-administration of venlafaxine and weight loss agents is not recommended. Venlafaxine is not indicated for weight loss alone or in combination with other products.</p><p>&nbsp;</p><p><strong>Mania/hypomania</strong></p><p>&nbsp;</p><p>Mania/hypomania may occur in a small proportion of patients with mood disorders who have received antidepressants, including venlafaxine. As with other antidepressants, venlafaxine should be used cautiously in patients with a history or family history of bipolar disorder.</p><p>&nbsp;</p><p><strong>Aggression</strong></p><p>&nbsp;</p><p>Aggression may occur in a sm all number of patients who have received antidepressants, including venlafaxine. This has been reported under initiation, dose changes and discontinuation of treatment.</p><p>&nbsp;</p><p>&nbsp;</p><p>As with other antidepressants, venlafaxine should be used cautiously in patients with a history of aggression.</p><p>&nbsp;</p><p><strong>Discontinuation of treatment</strong></p><p>&nbsp;</p><p>Withdrawal symptoms, when treatment is discontinued, are common, particularly if discontinuation is abrupt (see section 4.8). In clinical trials, adverse events seen on treatment</p><p>&nbsp;</p><p>&nbsp;</p><p>discontinuation (tapering and post-tapering) occurred in approximately 31% of patients treated with venlafaxine and 17% of patients taking placebo.</p><p>&nbsp;</p><p>&nbsp;</p><p>The risk of withdrawal symptoms may be dependent on several factors, including the duration and dose of therapy and the rate of dose reduction. Dizziness, sensory disturbances (including paraesthesia), sleep disturbances (including insomnia and intense dreams), agitation or anxiety, nausea and/or vomiting, tremor and headache are the most commonly reported reactions. Generally, these symptoms are mild to moderate; however, in some patients they may be severe in intensity. They usually occur within the first few days of discontinuing treatment, but there have been very rare reports of such symptoms in patients who have inadvertently missed a d ose. Generally, these symptoms are self- limiting and usually resolve within 2 w eeks, though in some individuals they may be prolonged (2-3 months or more). It is therefore advised that venlafaxine should be gradually tapered when discontinuing treatment over a period of several weeks or months, according to the patient&rsquo;s needs (see section 4.2).</p><p>&nbsp;</p><p><strong>Akathisia/psychomotor restlessness</strong></p><p>&nbsp;</p><p>The use of venlafaxine has been associated with the development of akathisia, characterised by a subjectively unpleasant or distressing restlessness and need to move often accompanied by an inability to sit or stand still. This is most likely to occur within the first few weeks of treatment. In patients who develop these symptoms, increasing the dose may be detrimental.</p><p>&nbsp;</p><p><u>Dry Mouth</u></p><p>&nbsp;</p><p>Dry mouth is reported in 10% of patients treated with venlafaxine. This may increase the risk of caries, and patients should be advised upon the importance of dental hygiene.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Monoamine Oxidase Inhibitors (MAOI) Irreversible non-selective MAOIs</strong></p><p>&nbsp;</p><p>Venlafaxine must not be used in combination with irreversible non-selective MAOIs. Venlafaxine must not be initiated for at least 14 days after discontinuation of treatment with an irreversible nonselective MAOI. Venlafaxine must be discontinued for at least 7 days before starting treatment with an irreversible non-selective MAOI (see sections 4.3 and 4.4).</p><p>&nbsp;</p><p><strong>Reversible, selective MAO-A inhibitor (moclobemide)</strong></p><p>&nbsp;</p><p>Due to the risk of serotonin syndrome, the combination of venlafaxine with a reversible and selective MAOI, such as moclobemide, is not recommended. Following treatment with a</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>reversible MAO- inhibitor, a shorter withdrawal period than 14 da ys may be used before initiation of venlafaxine treatment. It is recommended that venlafaxine should be discontinued for at least 7 days before starting treatment with a reversible MAOI (see section 4.4).</p><p>&nbsp;</p><p><strong>Reversible, non-selective MAOI (linezolid)</strong></p><p>&nbsp;</p><p>The antibiotic linezolid is a w eak reversible and non-selective MAOI and should not be given to patients treated with venlafaxine (see section 4.4).</p><p>&nbsp;</p><p>&nbsp;</p><p>Severe adverse reactions have been reported in patients who have recently been discontinued from an MAOI and started on venlafaxine, or have recently had venlafaxine therapy discontinued prior to initiation of an MAOI. These reactions have included tremor, myoclonus, diaphoresis, nausea, vomiting, flushing, dizziness, and hyperthermia with features resembling neuroleptic malignant syndrome, seizures, and death.</p><p>&nbsp;</p><p><strong>Serotonin syndrome</strong></p><p>&nbsp;</p><p>As with other serotonergic agents, serotonin syndrome may occur with venlafaxine treatment, particularly with concomitant use of other agents that may affect the serotonergic neurotransmitter system (including triptans, SSRIs, SNRIs, lithium, sibutramine, St. John&#39;s Wort [Hypericum perforatum], fentanyl and its analogues, tramadol, dextromethorphan, tapentadol, pethidine, methadone and pentazocine), with medicinal agents that impair metabolism of serotonin (such as MAOIs e.g. methylene blue), with serotonin precursors (such as tryptophan supplements) or with antipsychotics or other dopamine antagonists.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>If concomitant treatment of venlafaxine with an SSRI, an SNRI or a serotonin receptor agonist (triptan) is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases. The concomitant use of venlafaxine with serotonin precursors (such as tryptophan supplements) is not recommended (see section 4.4).</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>CNS-active substances</strong></p><p>&nbsp;</p><p>The risk of using venlafaxine in combination with other CNS-active substances has not been systematically evaluated. Consequently, caution is advised when venlafaxine is taken in combination with other CNS-active substances.</p><p>&nbsp;</p><p><strong>Ethanol</strong></p><p>&nbsp;</p><p>Venlafaxine has been shown not to increase the impairment of mental and motor skills caused by ethanol. However, as with all CNS-active substances, patients should be advised to avoid alcohol consumption.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Effect of other medicinal products on venlafaxine</strong></p><p>&nbsp;</p><p><strong>Ketoconazole (CYP3A4 inhibitor)</strong></p><p>&nbsp;</p><p>A pharmacokinetic study with ketoconazole in CYP2D6 extensive (EM) and poor metabolisers (PM) resulted in higher AUC of venlafaxine (70% and 21% in CYP2D6 PM and EM subjects, respectively) and O-desmethylvenlafaxine (33% and 23% in CYP2D6 PM and EM subjects, respectively) following administration of ketoconazole. Concomitant use of CYP3A4 inhibitors (e.g., atazanavir, clarithromycin, indinavir, itraconazole, voriconazole, posaconazole, ketoconazole, nelfinavir, ritonavir, saquinavir, telithromycin) and venlafaxine may increase levels of venlafaxine and O- desmethylvenlafaxine. Therefore, caution is advised if a patient&rsquo;s therapy includes a CYP3A4 inhibitor and venlafaxine concomitantly.</p><p>&nbsp;</p><p><strong>Effect of venlafaxine on other medicinal products</strong></p><p>&nbsp;</p><p><strong>Lithium</strong></p><p>&nbsp;</p><p>Serotonin syndrome may occur with the concomitant use of venlafaxine and lithium (see Serotonin syndrome).</p><p>&nbsp;</p><p><strong>Diazepam</strong></p><p>&nbsp;</p><p>Venlafaxine has no effects on the pharmacokinetics and pharmacodynamics of diazepam and its active metabolite, desmethyldiazepam. Diazepam does not appear to affect the pharmacokinetics of either venlafaxine or O-desmethylvenlafaxine. It is unknown whether a pharmacokinetic and/or pharmacodynamic interaction with other benzodiazepines exists.</p><p>&nbsp;</p><p><strong>Imipramine</strong></p><p>&nbsp;</p><p>Venlafaxine did not affect the pharmacokinetics of imipramine and 2-OH-imipramine. There was a dose-dependent increase of 2-OH-desipramine AUC by 2.5 to 4.5-fold when venlafaxine 75 mg to 150 mg daily was administered. Imipramine did not affect the pharmacokinetics of venlafaxine and O- desmethylvenlafaxine. The clinical significance of this interaction is unknown. Caution should be exercised with co-administration of venlafaxine and imipramine.</p><p>&nbsp;</p><p><strong>Haloperidol</strong></p><p>&nbsp;</p><p>A pharmacokinetic study with haloperidol has shown a 42% decrease in total oral clearance, a 70% increase in AUC, an 88% increase in Cmax, but no change in half-life for haloperidol. This should be taken into account in patients treated with haloperidol and venlafaxine concomitantly. The clinical significance of this interaction is unknown.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Risperidone</strong></p><p>&nbsp;</p><p>Venlafaxine increased the risperidone AUC by 50%, but did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone). The clinical significance of this interaction is unknown.</p><p>&nbsp;</p><p><strong>Metoprolol</strong></p><p>&nbsp;</p><p>Concomitant administration of venlafaxine and metoprolol to healthy volunteers in a pharmacokinetic interaction study for both medicinal products resulted in an increase of plasma concentrations of metoprolol by approximately 30-40% without altering the plasma concentrations of its active metabolite, &alpha;-hydroxymetoprolol. The clinical relevance of this finding in hypertensive patients is unknown. Metoprolol did not alter the pharmacokinetic profile of venlafaxine or its active metabolite, O-desmethylvenlafaxine. Caution should be exercised with co-administration of venlafaxine and metoprolol.</p><p>&nbsp;</p><p><strong>Indinavir</strong></p><p>&nbsp;</p><p>A pharmacokinetic study with indinavir has shown a 28% decrease in AUC and a 36% decrease in Cmax for indinavir. Indinavir did not affect the pharmacokinetics of venlafaxine and O-desmethylvenlafaxine. The clinical significance of this interaction is unknown.</p><p>&nbsp;</p><p><strong>Drugs that Prolong the QT Interval</strong></p><p>The risk of QTc prolongation and/or ventricular arrhythmias (e.g., TdP) is increased with concomitant use of other medicinal products which prolong the QTc interval. Coadministration of such medicinal products should be avoided (see section 4.4).</p><p>Relevant classes include:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; class Ia and III antiarrhythmics (e.g. quinidine, amiodarone, sotalol, dofetilide)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; some antipsychotics (e.g. thioridazine)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; some macrolides (e.g. erythromycin)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; some antihistamines</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; some quinolone antibiotics (e.g. moxifloxacin)</p><p>The above list is not exhaustive and other individual medicinal products known to significantly increase QT interval should be avoided.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Pregnancy</strong></p><p>&nbsp;</p><p>There are no adequate data from the use of venlafaxine in pregnant women. Studies in animals have shown reproductive toxicity (see section 5.3). The potential risk for humans is unknown. Venlafaxine must only be administered to pregnant women if the expected benefits outweigh any possible risk.</p><p>As with other serotonin reuptake inhibitors (SSRIs/SNRIs), discontinuation symptoms may occur in the newborns if venlafaxine is used until or shortly before birth. Some newborns exposed to venlafaxine late in the third trimester have developed complications requiring tube-feeding, respiratory support or prolonged hospitalisation. Such complications can arise immediately upon delivery.</p><p>&nbsp;</p><p>Epidemiological data have suggested that the use of SSRIs in pregnancy, particularly in late pregnancy, may increase the risk of persistent pulmonary hypertension in the newborn (PPHN). Although no studies have investigated an association of PPHN to SNRI treatment, this potential risk cannot be ruled out with Venex XR t aking into account the related mechanism of action (inhibition of the re-uptake of serotonin).</p><p>&nbsp;</p><p>&nbsp;</p><p>The following symptoms may be observed in neonates if the mother has used an SSRI/SNRI late in pregnancy: irritability, tremor, hypotonia, persistent crying, and difficulty in sucking or in sleeping. These symptoms may be due to either serotonergic effects or exposure symptoms. In the majority of cases, these complications are observed immediately or within 24 hours after partus.</p><p>&nbsp;</p><p><strong>Lactation</strong></p><p>&nbsp;</p><p>Venlafaxine and its active metabolite, O-desmethylvenlafaxine, are excreted in breast milk. A risk to the suckling child cannot be excluded. Therefore, a decision to continue/discontinue breast-feeding or to continue/discontinue therapy with Venex XR s hould be made, taking into account the benefit of breast-feeding to the child and the benefit of Venex XR therapy to the woman.</p><p>&nbsp;</p><p>There have been post-marketing reports of breast-fed infants who experienced crying, irritability, and abnormal sleep patterns. Symptoms consistent with venlafaxine drug discontinuation have also been reported after stopping breast-feeding.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p>Any psychoactive medicinal product may impair judgment, thinking, and motor skills. Therefore, any patient receiving venlafaxine should be cautioned about their ability to drive or operate hazardous machinery.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="0" cellpadding="0"><tbody><tr><td><p><br />The most commonly (&gt;1/10) reported adverse reactions in clinical studies were nausea, dry mouth, headache and sweating (including night sweats).</p><p>Adverse reactions are listed below by system organ class and frequency.</p><p>Frequencies are defined as: very common (&ge;1/10), common (&ge;1/100 to &lt;1/10), uncommon (&ge;1/1,000 to &lt;1/100), rare (&ge;1/10,000 to &lt;1/1,000), not known (cannot be estimated from the available data).</p><table border="1" cellspacing="0" cellpadding="0" align="left"><tbody><tr><td><p>Body System</p></td><td><p>Very Common</p></td><td><p>Common</p></td><td><p>Uncommon</p></td><td><p>Rare</p></td><td><p>Not Known</p></td></tr><tr><td><p>Blood and lymphatic system disorders</p></td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td><p>Thrombo-cytopaenia, Blood Disorder, including agranulocytosis, aplastic anaemia, neutropaenia, pancytopaenia</p></td></tr><tr><td><p>Immune system disorders</p></td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td><p>Anaphylactic reaction</p></td></tr><tr><td><p>Endocrine disorders</p></td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td><p>Syndrome of Inappropriate antidiuretic hormone secretion (SIADH)</p></td></tr><tr><td><p>Metabolism and nutrition disorders</p></td><td>&nbsp;</td><td><p>Decreased appetite</p></td><td>&nbsp;</td><td>&nbsp;</td><td><p>Hyponatraemia</p></td></tr><tr><td><p>Psychiatric disorders</p></td><td>&nbsp;</td><td><p>Confusional state, Depersonalization, Anorgasmia, Libido decreased, Nervousness, Insomnia, Abnormal dreams</p></td><td><p>Hallucination, Derealization, Agitation, Orgasm abnormal (female), Apathy, Hypomania, Bruxism</p></td><td><p>Mania</p></td><td><p>Suicidal ideation and suicidal behaviours*, Delirium, Aggression**</p></td></tr><tr><td><p>Nervous system disorders</p></td><td><p>Dizziness, Headache***</p></td><td><p>Somnolence, Tremor, Paraesthesia, Hypertonia</p></td><td><p>Akathisia/ Psychomotor restlessness, Syncope, Myoclonus, Coordination abnormal, Balance disorder, Dysgeusia</p></td><td><p>Convulsion</p></td><td><p>Neuroleptic Malignant Syndrome (NMS), Serotonergic syndrome, Extrapyramidal disorder, including dystonia and dyskinaesia, Tardive dyskinaesia</p></td></tr><tr><td><p>Eye disorders</p></td><td>&nbsp;</td><td><p>Visual impairment, including vision blurred, Mydriasis, Accommodation disorder</p></td><td>&nbsp;</td><td>&nbsp;</td><td><p>Angle-closure glaucoma</p></td></tr><tr><td><p>Ear and labyrinth disorders</p></td><td>&nbsp;</td><td><p>Tinnitus</p></td><td>&nbsp;</td><td>&nbsp;</td><td><p>Vertigo</p></td></tr><tr><td><p>Cardiac disorders</p></td><td>&nbsp;</td><td><p>Palpitations</p></td><td><p>Tachycardia</p></td><td>&nbsp;</td><td><p>Ventricular fibrillation, Ventricular tachycardia (including Torsade de Pointes)</p></td></tr><tr><td><p>Vascular disorders</p></td><td>&nbsp;</td><td><p>Hypertension, Vasodilatation (mostly flush)</p></td><td><p>Orthostatic hypotension</p></td><td>&nbsp;</td><td><p>Hypotension, Bleeding (mucous membrane bleeding)</p></td></tr><tr><td><p>Respiratory, thoracic and mediastinal disorders</p></td><td>&nbsp;</td><td><p>Yawning</p></td><td><p>Dyspnoea</p></td><td>&nbsp;</td><td><p>Pulmonary eosinophilia</p></td></tr><tr><td><p>Gastrointestinal disorders</p></td><td><p>Nausea, Dry mouth</p></td><td><p>Vomiting, Diarrhoea, Constipation</p></td><td><p>Gastrointestinal haemorrhage</p></td><td>&nbsp;</td><td><p>Pancreatitis</p></td></tr><tr><td><p>Hepatobiliary disorders</p></td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td><p>Hepatitis, Liver function test abnormal</p></td></tr><tr><td><p>Skin and subcutaneous tissue disorders</p></td><td><p>Hyperhidrosis (including night sweats)</p></td><td>&nbsp;</td><td><p>Angioedema, Photosensitivity reaction, Ecchymosis, Rash, Alopecia</p></td><td>&nbsp;</td><td><p>Stevens-Johnson syndrome, Erythema multiforme, Toxic epidermal necrolysis, Pruritus, Urticaria</p></td></tr><tr><td><p>Musculoskeletal and connective tissue disorders</p></td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td><p>Rhabdomyolysis</p></td></tr><tr><td><p>Renal and urinary disorders</p></td><td>&nbsp;</td><td><p>Dysuria (mostly urinary hesitation), Pollakiuria</p></td><td><p>Urinary retention</p></td><td><p>Urinary incontinence</p></td><td>&nbsp;</td></tr><tr><td><p>Reproductive system and breast disorders</p></td><td>&nbsp;</td><td><p>Menstrual disorders associated with increased bleeding or irregular bleeding (e.g. menorrhagia, metrorrhagia), Ejaculation disorder, Erectile dysfunction</p></td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td><p>General disorders and administration site conditions</p></td><td>&nbsp;</td><td><p>Asthenia, Fatigue, Chills</p></td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td><p>Investigations</p></td><td>&nbsp;</td><td><p>Blood cholesterol increased</p></td><td><p>Weight increased, Weight decreased</p></td><td>&nbsp;</td><td><p>Electro-cardiogram QT prolonged, Bleeding time prolonged, Blood prolactin increased</p></td></tr></tbody></table><p>*Cases of suicidal ideation and suicidal behaviours have been reported during venlafaxine therapy or early after treatment discontinuation (see section 4.4).</p><p>**See section 4.4</p><p>***In pooled clinical trials, the incidence of headache with venlafaxine and placebo were similar.</p><p>Discontinuation of venlafaxine (particularly when abrupt) commonly leads to withdrawal symptoms. Dizziness, sensory disturbances (including paraethesia), sleep disturbances (including insomnia and intense dreams), agitation or anxiety, nausea and/or vomiting, tremor, vertigo, headache and flu syndrome are the most commonly reported reactions. Generally, these events are mild to moderate and are self-limiting; however, in some patients, they may be severe and/or prolonged. It is therefore advised that when venlafaxine treatment is no longer required, gradual discontinuation by dose tapering should be carried out (see sections 4.2 and 4.4).</p><p><u>Paediatric patients</u></p><p>In general, the adverse reaction profile of venlafaxine (in placebo-controlled clinical trials) in children and adolescents (ages 6 to 17) was similar to that seen for adults. As with adults, decreased appetite, weight loss, increased blood pressure, and increased serum cholesterol were observed (see section 4.4).</p><p>In paediatric clinical trials the adverse reaction suicidal ideation was observed. There were also increased reports of hostility and, especially in major depressive disorder, self-harm.</p><p>Particularly, the following adverse reactions were observed in paediatric patients: abdominal pain, agitation, dyspepsia, ecchymosis, epistaxis, and myalgia</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p><strong>To report any side effect(s):<em> </em></strong></p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p> The National Pharmacovigilance and Drug Safety Centre (NPC)</p><p>o Fax: +966-11-205-7662</p><p>o Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.</p><p>o Toll free phone: 8002490000</p><p>o E-mail: npc.drug@sfda.gov.sa</p><p>o Website: www.sfda.gov.sa/npc</p><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In postmarketing experience, overdose with venlafaxine was reported predominantly in combination with alcohol and/or other medicinal products. The most commonly reported events in overdose include tachycardia, changes in level of consciousness (ranging from somnolence to coma), mydriasis, convulsion, and vomiting. Other reported events include electrocardiographic changes (e.g., prolongation of QT interval, bundle branch block, QRS prolongation), ventricular tachycardia, bradycardia, hypotension, vertigo, and death.</p><p>&nbsp;</p><p>&nbsp;</p><p>Published retrospective studies report that venlafaxine overdosage may be associated with an increased risk of fatal outcomes compared to that observed with SSRI antidepressant products, but lower than that for tricyclic antidepressants. Epidemiological studies have shown that venlafaxine-treated patients have a higher burden of suicide risk factors than SSRI patients. The extent to which the finding of an increased risk of fatal outcomes can be attributed to the toxicity of venlafaxine in overdosage, as opposed to some characteristics of venlafaxine-treated patients, is not clear. Prescriptions for venlafaxine should be written for the smallest quantity of the medicinal product consistent with good patient management in order to reduce the risk of overdose.</p><p>&nbsp;</p><p><strong>Recommended treatment</strong></p><p>&nbsp;</p><p>General supportive and symptomatic measures are recommended; cardiac rhythm and vital signs must be monitored. When there is a risk of aspiration, induction of emesis is not recommended. Gastric lavage may be indicated if performed soon after ingestion or in symptomatic patients. Administration of activated charcoal may also limit absorption of the active substance. Forced diuresis, dialysis, hemoperfusion and exchange transfusion are unlikely to be of benefit. No specific antidotes for venlafaxine are known.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Pharmacotherapeutic group</u></strong>: Other antidepressants - ATC code: NO6A X16.</p><p>&nbsp;</p><p>The mechanism of venlafaxine&#39;s antidepressant action in humans is believed to be associated with its potentiation of neurotransmitter activity in the central nervous system. Preclinical studies have shown that venlafaxine and its major metabolite, O-desmethylvenlafaxine (ODV), are inhibitors of serotonin and noradrenaline reuptake. Venlafaxine also weakly inhibits dopamine uptake. Venlafaxine and its active metabolite reduce &beta;-adrenergic responsiveness after both acute (single dose) and chronic administration. Venlafaxine and ODV are very similar with respect to their overall action on neurotransmitter reuptake and receptor binding.</p><p>&nbsp;</p><p>Venlafaxine has virtually no a ffinity for rat brain muscarinic, cholinergic, H1-histaminergic or &alpha;1- adrenergic receptors in vitro. Pharmacological activity at these receptors may be related to various side effects seen with other antidepressant medicinal products, such as anticholinergic, sedative and cardiovascular side effects.</p><p>&nbsp;</p><p>Venlafaxine does not possess monoamine oxidase (MAO) inhibitory activity.</p><p>&nbsp;</p><p>In vitro studies revealed that venlafaxine has virtually no affinity for opiate or benzodiazepine sensitive receptors.</p><p>&nbsp;</p><p><strong>Major depressive episodes</strong></p><p>&nbsp;</p><p>The efficacy of venlafaxine immediate-release as a treatment for major depressive episodes was demonstrated in five randomised, double-blind, placebo-controlled, short-term trials ranging from 4 to 6 weeks duration, for doses up t o 375 m g/day. The efficacy of venlafaxine prolonged-release as a</p><p>&nbsp;</p><p>treatment for major depressive episodes was established in two placebo-controlled, short-term studies for 8 and 12 weeks duration, which included a dose range of 75 to 225 mg/day.</p><p>&nbsp;</p><p>In one longer-term study, adult outpatients who had responded during an 8-week open trial on venlafaxine prolonged-release (75, 150, o r 225 m g) were randomised to continuation of their same venlafaxine prolonged-release dose or to placebo, for up to 26 weeks of observation for relapse.</p><p>&nbsp;</p><p>In a second longer-term study, the efficacy of venlafaxine in prevention of recurrent depressive episodes for a 12-month period was established in a placebo-controlled double-blind clinical trial in adult outpatients with recurrent major depressive episodes who had responded to venlafaxine treatment (100 to 200 mg/day, on a b.i.d. schedule) on the last episode of depression.</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p><strong>Social anxiety disorder</strong></p><p>&nbsp;</p><p>The efficacy of venlafaxine prolonged-release capsules as a treatment for social anxiety disorder was established in four double-blind, parallel-group, 12-week, multi-center, placebo-controlled, flexible- dose studies and one double-blind, parallel-group, 6-month, placebo-&nbsp; controlled, fixed/flexible-dose study in adult outpatients. Patients received doses in a range of 75 to 225 mg/day. There was no evidence for any greater effectiveness of the 150 to 225 mg/day group compared to the 75 m g/day group in the 6-month study.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Venlafaxine is extensively metabolised, primarily to the active metabolite, O-desmethylvenlafaxine (ODV). Mean &plusmn; SD plasma half-lives of venlafaxine and ODV are 5&plusmn;2 hours and 11&plusmn;2 hours, respectively. Steady-state concentrations of venlafaxine and ODV are attained within 3 days of oral multiple-dose therapy. Venlafaxine and ODV exhibit linear kinetics over the dose range of 75 m g to</p><p>450 mg/day.</p><p>&nbsp;</p><p><strong>Absorption</strong></p><p>&nbsp;</p><p>At least 92% of venlafaxine is absorbed following single oral doses of immediate-release venlafaxine. Absolute bioavailability is 40% to 45% due to presystemic metabolism. After immediate-release venlafaxine administration, the peak plasma concentrations of venlafaxine and ODV occur in 2 and 3 hours, respectively. Following the administration of venlafaxine prolonged-release capsules, peak plasma concentrations of venlafaxine and ODV are attained within 5.5 hours and 9 hours, respectively. When equal daily doses of venlafaxine are administered as either an immediate-release tablet or prolonged-release capsule, the prolonged-release capsule provides a sl ower rate of absorption, but the same extent of absorption compared with the immediate-release tablet. Food does not affect the bioavailability of venlafaxine and ODV.</p><p>&nbsp;</p><p><strong>Distribution</strong></p><p>&nbsp;</p><p>Venlafaxine and ODV are minimally bound a t therapeutic concentrations to human plasma proteins (27% and 30%, respectively). The volume of distribution for venlafaxine at steady-state is 4.4&plusmn;1.6 L/kg following intravenous administration.</p><p>&nbsp;</p><p><strong>Metabolism</strong></p><p>&nbsp;</p><p>Venlafaxine undergoes extensive hepatic metabolism. In vitro and in vivo studies indicate that venlafaxine is biotransformed to its major active metabolite, ODV, by CYP2D6. In vitro and in</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:bottom"><p>vivo studies</p></td><td style="vertical-align:bottom"><p>indicate&nbsp; that&nbsp; venlafaxine&nbsp; is&nbsp; metabolised&nbsp; to&nbsp; a m inor,&nbsp; less&nbsp; active</p></td></tr><tr><td style="vertical-align:bottom"><p>metabolite,</p></td><td style="vertical-align:bottom"><p>N- desmethylvenlafaxine, by CYP3A4. In vitro and in vivo studies indicate that</p></td></tr></tbody></table><p>&nbsp;</p><p>venlafaxine is a weak inhibitor of CYP2D6. Venlafaxine did not inhibit CYP1A2, CYP2C9, or CYP3A4.</p><p>&nbsp;</p><p><strong>Elimination</strong></p><p>&nbsp;</p><p>Venlafaxine and its metabolites are excreted primarily through the kidneys. Approximately 87% of a venlafaxine dose is recovered in the urine within 48 hours as either unchanged venlafaxine (5%), unconjugated ODV (29%), conjugated ODV (26%), or other minor inactive metabolites (27%). Mean &plusmn; SD plasma steady-state clearances of venlafaxine and ODV are 1.3&plusmn;0.6 L/h/kg and 0.4&plusmn;0.2 L/h/kg, respectively.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Special populations</strong></p><p>&nbsp;</p><p><strong>Age and gender</strong></p><p>&nbsp;</p><p>Subject age and gender do not significantly affect the pharmacokinetics of venlafaxine and ODV.</p><p>&nbsp;</p><p><strong>CYP2D6 extensive/poor metabolisers</strong></p><p>&nbsp;</p><p>Plasma concentrations of venlafaxine are higher in CYP2D6 poor metabolisers than extensive metabolisers. Because the total exposure (AUC) of venlafaxine and ODV is similar in poor and extensive metabolisers, there is no need for different venlafaxine dosing regimens for these two groups.</p><p>&nbsp;</p><p><strong>Patients with hepatic impairment</strong></p><p>&nbsp;</p><p>In Child-Pugh A (mildly hepatically impaired) and Child-Pugh B (moderately hepatically impaired)</p><p>&nbsp;</p><p>subjects, venlafaxine and ODV half-lives were prolonged compared to normal subjects. The oral clearance of both venlafaxine and ODV was reduced. A large degree of intersubject variability was noted. There are limited data in patients with severe hepatic impairment (see section 4.2).</p><p>&nbsp;</p><p><strong>Patients with renal impairment</strong></p><p>&nbsp;</p><p>In dialysis patients, venlafaxine elimination half-life was prolonged by about 180% and clearance reduced by about 57% compared to normal subjects, while ODV elimination halflife was prolonged by about 142% and clearance reduced by about 56%. Dosage adjustment is necessary in patients with</p><p>severe renal impairment and in patients that require haemodialysis (see section 4.2).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Studies with venlafaxine in rats and mice revealed no evidence of carcinogenesis. Venlafaxine was not mutagenic in a wide range of in vitro and in vivo tests.</p><p>&nbsp;</p><p>Animal studies regarding reproductive toxicity have found in rats a decrease in pup weight, an increase in stillborn pups, and an increase in pup de aths during the first 5 da ys of lactation. The cause of these deaths is unknown. These effects occurred at 30 mg/kg/day, 4 times the human daily dose of 375 mg of venlafaxine (on an mg/kg basis). The no-effect dose for these findings was 1.3 times the human dose. The potential risk for humans is unknown.</p><p>&nbsp;</p><p>Reduced fertility was observed in a study in which both male and female rats were exposed to ODV. This exposure was approximately 1 t o 2 t imes that of a human venlafaxine dose of 375 mg/day. The human relevance of this finding is unknown.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Each prolonged-release capsule, hard contains 37.5 mg, 75 mg and 150 mg of Venex XR as venlafaxine hydrochloride.</p><p>&nbsp;</p><p>The other ingredients are:</p><p>37.5 mg prolonged-release capsules, hard:</p><p>Capsule content: Hydromellose (Methocel K 100M), Eudragit RS 100 powder, Sodium lauryl sulphate, Magnesium stearate, and ethanol</p><p>&nbsp;</p><p>Coating: Eudragit E 12.5, and Isopropyl alcohol</p><p>&nbsp;</p><p>Capsule shell: Titanium Dioxide E 171, Gelatin</p><p>&nbsp;</p><p>&nbsp;</p><p>75 mg prolonged-release capsules, hard:</p><p>&nbsp;</p><p>Capsule content: Hydromellose (Methocel K 100M), Eudragit RS 100 powder, Sodium lauryl sulphate, Magnesium stearate</p><p>&nbsp;</p><p>Coating: Eudragit E 100</p><p>&nbsp;</p><p>Capsule shell: Titanium Dioxide E 171, Iron Oxide (Red) E172, Gelatin</p><p>&nbsp;</p><p>150 mg prolonged-release capsules, hard:</p><p>&nbsp;</p><p>Capsule content: Hydromellose (Methocel K 100M), Eudragit RS 100 powder, Sodium lauryl sulphate, Magnesium stearate</p><p>&nbsp;</p><p>Coating: Eudragit E 100</p><p>&nbsp;</p><p>Capsule shell: Titanium Dioxide E 171, Erythrosine E 127, Indigo Carmine E132, Gelatin</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&minus; Not Applicable.</p><p><strong><em>&nbsp;</em></strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                − 3 Years/36 months.


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not store above 30&ordm;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>PVC/PE/PVDC/Al blister</p><p>&nbsp;</p><p>37.5 mg: 10, 14, 28, 30 and 98 prolonged-release capsules, hard 75 mg: 10, 14, 28, 30, 60 and 98 prolonged-release capsules, hard 150 mg: 10, 14, 28, 30, 60 and 98 prolonged-release capsules, hard</p><p>&nbsp;</p><p>Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements for disposal.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Manufactured by
Pharmathen
For
SPIMACO
Al-Qassim pharmaceutical plant
Saudi Pharmaceutical Industries &
Medical Appliance Corporation.
Saudi Arabia

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                
This leaflet was last approved in May 2018

            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>